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The segregation and upkeep of distinct compartmental organization within the cell requires both 
organelle specific SNAREs as well as sorting receptors to allow for continual rounds of productive 
fusion bringing in appropriate cargo into designated organelles.  Generally, sorting receptors 
function by providing unique signal sequences in the c-terminal tail region of the receptor that bind 
to specific sorting proteins allowing cargo to be transmitted to appropriate organelles.  However, 
the yeast Vps10 vacuolar sorting protein functions by an as yet undefined signal sequence 
segregating proteins to either the secretory pathway or to the vacuole.  Additionally, we have found 
that the mammalian Vps-10 orthologue, sortilin binds to PI(3,4,5)tri-phosphate (PIP3) and this 
may have relevance to the eventual sorting functions in this pathway.  Furthermore, this pathway 
is defined by its requirement for the protein Vps-34, the only class III phosphatidyl-inositol-3-
kinase that makes PI3P in both yeast and mammalian cells.  The relationship between Vps-34 or 
PI3P production and phosphatidic acid (PA) levels is a fairly unexplored subject.  However, our 
group identified the PA phosphatase Pah1 as being the sole PA phosphatase, which when knocked 
out showed any effect on yeast vacuole fusion.  Furthermore, in Pah1 knockouts, there is no Vps34 
at the yeast vacuole and levels of PI3P at the yeast vacuole are almost completely abolished.  We 
have shown that PA levels at the vacuole affect fusion via regulation at the priming step of fusion.  
Priming is the unraveling of cis-SNAREs resulting from trans-SNARE complexes remaining from 
a prior fusion event. The unique job of priming all cellular SNAREs is the responsibility of AAA+ 
ATPase NSF or Sec18, which transmits the energy released from ATP hydrolysis to mechanically 
unwind SNAREs.  In order to investigate Vps10 dependent sorting and SNARE priming, small 
molecules were developed to probe the lipid binding pockets of both yeast Vps-10 and Sec18.  
These molecules have been shown to affect levels of priming as well as targets of sorting protein 
Vps-10.  It is proposed that computational drug discovery in companion with molecular dynamics 
(MD) simulations can be coupled to biochemical techniques to further elucidate mechanisms of 
protein fusion and sorting involving specific lipid-protein interactions to further understand the 
mechanisms by which pathways such as the Vps-10 protein sorting pathway and the yeast fusion 
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My parents (M.D. Professor Charles Edward Sparks) and my mother had found a new favorite 
protein sortilin, a sorting receptor for the biomolecule VLDL/LDL (defined by the presence of 
ApoB-ApoB I had learned of at the ripe age of four years old).  I remember my parents taking me 
to New Hampshire for my first Gordon Conference, which consisted to me in the end of playing 
skee-ball at a local amusement park, and generally bouncing on the bed in the hotel room while I 
watched Larry Legend play Magic Johnson in the NBA Finals that year.  My parents asked me for 
one of my books teaching the alphabet, specifically the book pertaining to the letter B.  B is for 
baboon, balloon, etc. with pictures for each reference.  My parents were using this book for a talk 
on ApoB that they were to present at the conference.  Little did I know, through herculean efforts 
on my part to not be interested in such trivial fantasies such as are the pursuit of Science to a child 
brought up around it might consist of, I circled back to this protein almost 30 years later. 
 
My mother worked tirelessly in the lab that consisted of a mom and pop shop, with lab techs and 
a select few graduate and undergraduate students.  However, this small lab was well respected in 
the field starting with my father’s discovery of two forms of ApoB (B48 and B100) and followed 
on by several important discoveries including those relating to ApoBec, the mRNA editing enzyme 
responsible for generating these two B48 and its progenitor. Another more recent one was the 
requirement for Vps34 involved in insulin dependent ApoB degradation, fittingly to me named 
IDAD, a running joke in our family-and the recent one in the Fratti lab is similar, inhibitor of 
priming activity or IPA, which happens to be Rudy’s favorite beer or at least if it isn’t it is growing 
favor.  This work ethic and ability to enjoy scientific experimentation translated well to me when 
I had finally grown a passion for science-after a circuitous path through 4 years in the Navy (8 
month deployment Persian Gulf) on an aircraft carrier, two law school programs, and even a 
Religion degree.  An experience with my mother in our 3 years of experimentation during my 
Scientific training at the University of South Florida in Biochemistry,  my mother and I shared 
drives to the lab, carrying literature duties from the parking lot in Rochester in winter (very cold 
sometimes) to the lab, drawing out metabolic pathways on the chalkboard, and my eventual 
begging to see the results of our most recent at experiment at the end of each session.  
 
It seemed when I reached graduate school, my enthusiasm for experimentation never dissipated.  
The important thing about my mother performing the experiments herself was that you knew the 
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results were accurate and as my father would say, “there is no one better in the lab than your 
mother.”  That being said, you had to literally pry the results out of her as she always focused on 
her mistakes at first, before she gave in and conceded that the results were probably accurate and 
would allow you to see them.  The reasoning behind my excitement (and annoyance to those who 
slow down my immediate gratification in scientific results) was just that, I wanted to know the 
answer, and each experiment led to an experiment that could at least provide some tangential proof 
of some scientific truth.  This was what I was hungry for, answers.   
 
Throughout my life I idolized both my father and his father William Sparks (whom I never met).  
My father was a Navy surgeon and this led to my decision to join the Navy.  However, this was 
entirely unfair to my mother, and in the end, her ability to support this notion with little deference 
to her own success was truly a remarkable example of what it means to be a good person.  The 
super-hero type ideal embodied by my father and the uncanny ability to remain humble represented 
by mother and her father, lead me still today to achieve things that others might not even think to 
try.  My grandfather Ronald visited every single Presbyterian Church in the country before his 
death.  I found mine in the Navy as a result of my long time Navy friend, Father Mark Bristol 
(Formally, this thesis is also dedicated to him and his Boss as well).  Regardless, my mother’s 
unwavering support of me through this circuitous path rivals even Mark, and is the predominant 
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CHAPTER 1: Introduction 
 
George Palade indicated in 1974 that understanding the secretory process depends on the 
chemistry of reactions on membranes, with Schekman et al. choosing Saccharomyces 
cerevisiae as the model system to study such interactions (1, 2). The yeast vacuole resembles 
the orthologous mammalian lysosome with both serving as the terminal stage of the endocytic, 
and autophagic pathways. In yeast, the importance of this organelle is accentuated as the 
morphology of the vacuole alone can reflect defects in sorting to the organelle (3). The 
carboxypeptidase Y (CPY) pathway traffics from the trans-Golgi-Network (TGN) to the 
vacuole and is a classic protein of interest for genetic classifications in yeast. Vps10 (yeast 
orthologue to hsortilin) sorts CPY directly and is implicated in trafficking various other 
hydrolases to the vacuole (PrA and PrB). Fusion assays measure luminal content mixing of 
vesicles targeted to the vacuole centric baker’s yeast (baker’s yeast having large and generally 
circular vacuole), and measurements of mixing (fusion) have been devised in numerous ways. 
For example, the vacuolar protease Pep4/PrA is required for maturation of the CPY TGN 
isoform p2CPY (69 kD) to mCPY (61 kD), thus, vacuoles lacking Pep4, but containing p2CPY 
can be incubated with vacuoles that lack p2CPY but harbor Pep4. The result of fusion and 
mixture of contents of these vacuoles would be proteolysis of p2CPY to mCPY, which can be 
resolved by immunoblotting (4-6). However, this experimental setup requires western blotting 
so labs use assays with genetic mutations allowing colorometric detection of fusion reactions 
(7). Utilizing these types of experimens, a researcher could therefore study either the fusion 
machinery directly (Chapter 2 and 3) or a sorting receptor with its destination focused towards 
the vacuole or lysosome (Chapter 4).  Furthermore, to a researcher interested in mechanistic 
explanation, one can additionally focus on evolutionary mechanistic observations as between 







Stages of Vacuole Fusion 
The stages of vacuole fusion include: 1) Priming: cis-SNARE complex disassembly by the 
AAA+ protein Sec18; 2) Tethering: the reversible binding of vesicle by the tethering complex 
HOPS organized by the Rab GTPase Ypt7; 3) Docking: formation of trans-SNARE complexes 
between 3 Q-SNAREs on one membrane and one R-SNARE on the partner vesicle. At this 
stage, SNAREs, Ypt7, and HOPS assemble into a microdomain named the vertex ring along 
with regulatory lipids that include phosphoinositides (PI), diacylglycerol (DAG) and 
phosphatidic acid (PA); and 4) Fusion of lipid bilayers stemming from vertices of adjacent 
vesicles forming continuous membrane eventually culminating in mixing of luminal contents 
and leaving new cis-SNARE complexes (7,8).  Chapter 2 and Chapter 3 focus on Sec18, 
required at organelles that undergo priming.  Priming occurs at nearly every organelle except 
for the mitochondria.  Information about how priming is regulated has biological significance 
cell wide. 
 
Lipid Regulation of Vacuole Fusion 
Stoichiometry of vacuolar lipids is dynamic throughout the fusion pathway and is required for 
protein function and recruitment facilitating fusion. For example, PA is converted to DAG by 
the PA phosphatase Pah1 in order to initiate priming (3). Later, the PI 3-kinase Vps34 produces 
more PI3P attracting binding of soluble Q-SNARE Vam7 during tethering/docking, after 
which PI3P aids in assembly of vertex microdomains. PI3P is also important for endocytic 
trafficking and autophagy. Although these and other lipids are essential for membrane fusion, 
much remains to be discovered both mechanistically and pathologically on the interplay 
between lipid types resulting in large scale biological phenomenon.  PA and PI3P are inversely 
proportional to the beginning and end of fusion.  The regulatory lipid PA is the focus of Chapter 
3, whereas the regulatory lipid PI3P is the focus of Chapter 4.  Additionally, the formation and 
trafficking of proteins requiring PI3P signaling has been a focus of the Fratti lab with regard 
yielding synergies in exploring the Vps34 dependent autophagic complex in Chapter 4.   
 
PA:DAG Ratios at the Yeast Vacuole 
Stoichiometry of vacuolar DAG:PA can directly impact fusion. For instance, vacuoles from 
cells where DAG kinase Dgk1 is absent show increased fusion presumably from increased 
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DAG promoting membrane fluidity and activation of Rab Ypt7 (9). Additionally, we have 
proposed PA inhibits fusion through sequestration of Sec18 away from cis-SNAREs (10). 
Importantly, dgk1 vacuoles require an elevated amount of PA to inhibit fusion relative to wild 
type vacuoles resulting in an increased IC50 for PA inhibition of fusion (7). Both phospholipase 
D (PLD) and Dgk1 enzymatically generate PA on the vacuole membrane, albeit by different 
mechanisms. Our lab has shown that Pah1 is a potent regulator of Sec18 presumably 
controlling physical dynamic levels of PA and DAG at precise vacuolar membrane locations 
in response to fusion relevant regulatory mechanisms. The dgk1 pah1 double deletion 
rescues the effects of deleting PAH1 alone at the endoplasmic reticulum, however, this does 
not occur at the vacuole with respect to fusion (9). Furthermore, other yeast PA phosphatases 
when deleted do not change fusion levels. It is hypothesized that even though PA:DAG 
stoichiometry alone can serve to regulate membrane fusion, stoichiometric ratio of these lipids 
is not solely responsible for fusion related effects of pah1 vacuoles. 
 
Sec18 is a AAA+ family member that binds to PA with high affinity (Fig. 1A) (10). Sec18 
consists of 3 domains (N, D1, and D2) that polymerize to form a homohexameric structure 
capable of hydrolyzing ATP to secure energy necessary for unbundling cis-SNARE 
complexes. It is hypothesized that Sec18 has a well-defined PA binding site that serves a 
precise regulatory function in priming vesicles for membrane fusion (11). The PA phosphatase 
Pah1 is thought to play a direct role in releasing Sec18 from a PA-bound state by conversion 
of PA to DAG (10). Mechanisms of Sec18 interaction with PA had not been thoroughly 
characterized until recently (see Chapter 2 and Chapter 3).   
 
Vps34 Dependent PI3P Regulation 
Vps34 is the only yeast PI3-kinase and is part of two prototypical heterotetrameric complexes, 
however, it appears probable that there are many permutations of complexes involving Vps34 
with various functions effecting ranging fields of interest including trafficking, autophagy, cell 
metabolism, and cancer. Autophagic Complex I contains Vps15, Atg14, and Atg38, whereas 
the endosomal Complex II harbors Vps15, Vps30, and Vps38, however, additional complexes 
envisioned (12). My work focuses on Complex II.  Interestingly, mammalian literature (13) 
lacks literature on Vps34 presence at the TGN, whereas Emr, Sheckman, and Ohsumi discuss 
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Vps34 function directly at the yeast TGN. Importantly, Vps34 is required for endocytic clathrin 
dependent traffic to the endosome and Vps10 is required for anterograde traffic from the TGN 
to the endosome.  Vps10 activity at the plasma membrane is not as well defined as sortilin in 
endocytic trafficking, where sortilin is known to bind to extracellular proteins facilitating 
endocytosis.  It is hypothesized that the activation of Complex II Vps34 (and eventual 
production of PI3P stemming from association of Vps15 and Vps34) can occur in response to 
binding events in the lumen of the trans-Golgi, e.g. binding of Vps10 to p2CPY. Direct binding 
of Vps10 to a cargo of interest is hypothesized to trigger a conformational change in Vps10 
that is transmitted through the TM of Vps10 either through the C-terminal tail or through 
interactions between lipids or proteins nearby to the TM, activating Vps34 in the absence of a 
canonical anterograde or secretory signaling sequence.  Membrane dependent interactions can 
be mediated by specific phospholipid environments called membrane rafts.   
 
Similar to PA and DAG, PI3P is essential for membrane fusion and proper trafficking to the 
vacuole. PI3P serves to recruit PLD resulting in activation of mTORC1, and this process 
inhibits formation of Complex I (autophagy) while stimulating Complex II through 
phosphorylation of Vps38 present in Complex II (14). Furthermore, Emr et al. upon discovery 
of both Vps10 and Vps34 in the early 90’s the possibility that Vps10 may bind to either Vps34 
or Vps15 via its C-terminal tail (31).  Vps15 often contains a myristoylated anchor securing its 
cytosolic partner Vps34 to the membrane. It is hypothesized that PI3P generation beginning at 
the TGN stimulates vesicle delivery of Vps10-bound p2CPY to the endosome where CPY is 
sorted to the vacuole. Vps10 dependent anterograde trafficking to the vacuole does not appear 
to be signal sequence dependent (15).   
 
Vps34 Dependent Trafficking to Lysosome by Sortilin/Vps10 
Cargo sorting can be modulated by small molecule administration of Vps10/sortilin targeted 
compounds (Chapter 4) leading to measured changes in protein trafficking patterns. The 
mechanism of this action will be characterized to better understand how luminal cargo binding 
can change trafficking patterns of nascent vesicles (13). It is hypothesized that these molecules 
alter affinities of Vps10 for various cargo, thereby changing trafficking patterns.  Importantly, 
in humans sortilin has been linked to cardiovascular disease and has been shown to bind the 
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Kex2/Furin family inactive protease PCSK9 which is secreted from mammalian cells binding 
to the LDL receptor and endocytosing with that receptor to get degraded at the lysosome. In 
yeast, Vps10 has been shown to bind to the active vacuolar protease CPY that is predominantly 
not secreted (16, 17).  Evolutionary differences in protease-scaffold dependent trafficking may 
be implicated by new mechanistic insights into cargo dependent sorting.  Small molecules 
targeting site 2 of sortilin and also the region where PCSK9 binds LDL receptor have been 
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Eukaryotic cell homeostasis requires transfer of cellular components among organelles and relies 
on membrane fusion catalyzed by SNARE proteins. Inactive SNARE bundles are reactivated by 
hexameric N-ethylmaleimide–sensitive factor, vesicle fusing ATPase (Sec18/NSF)-driven 
disassembly that enables a new round of membrane fusion. We previously found that phosphatidic 
acid (PA) binds Sec18 and thereby sequesters it from SNAREs and that PA dephosphorylation 
dissociates Sec18 from the membrane, allowing it to engage SNARE complexes. We now report 
that PA also induces conformational changes in Sec18 protomers and that hexameric Sec18 cannot 
bind PA membranes. Molecular dynamics (MD) analyses revealed that the D1 and D2 domains of 
Sec18 contain PA-binding sites and that the residues needed for PA binding are masked in 
hexameric Sec18. Importantly, these simulations also disclosed that a major conformational 
change occurs in the linker region between the D1 and D2 domains, which is distinct from the 
conformational changes that occur in hexameric Sec18 during SNARE priming. Together, these 
findings indicate that PA regulates Sec18 function by altering its architecture and stabilizing 




Membrane fusion is necessary for all eukaryotes to effectively transport cellular components 
between organelles. The trafficking and fusion of vesicles is carried out through a series of events 
that are highly conserved across eukarya (1). Although many proteins that drive the process may 
differ between eukaryotic species, they all perform similar roles allowing compartment contact, 
 
1 This chapter appeared in its entirety in the Journal of Biological Chemistry, Matthew L. Starr, Robert P. Sparks, 
Andres S. Arango, Logan R. Hurst, Zhiyu Zhao1, Muyun Lihan, Jermaine L. Jenkins, Emad Tajkhorshid and Rutilio 
A. Fratti (2018) Phosphatidic acid induces conformational changes in Sec18 protomers that prevent SNARE 
priming. Journal of Biological Chemistry 294, 3100-3116.  This article is reprinted with permission from the 




bilayer fusion, and luminal content mixing (2). The final stage of membrane fusion, and luminal 
content mixing, is catalyzed by SNARE proteins. Each participating membrane contributes either 
an R-SNARE or three QSNARE coils that wrap around each other to form a parallel four-helical 
trans-SNARE complex that brings membranes into close apposition. The formation of such 
complexes releases free energy that is transmitted to the membranes to trigger fusion. Once fusion 
occurs and membranes are merged, the four helical SNARE bundle, now a cis-SNARE complex, 
is inactive and requires disassembly in order to undergo a new round of fusion.   
  
The disassembly of cis-SNAREs, also known as Priming, is carried out by the AAA+ protein  
Sec18/NSF and its adaptor protein Sec17/a-SNAP (3) (Fig. 2.1A). Current models suggest that 
NSF primes cis-SNAREs through a “loaded-spring” mechanism triggered by cis-SNARE 
recognition and ATP hydrolysis (4). NSF binds to cis-SNAREs with the help of a-SNAP to form 
what is known as the 20S complex (5–8). Although NSF was originally isolated as a trimer or 
tetramer, it can only prime SNAREs as a homohexamer that surrounds the cis-SNAREs and a-
SNAP proteins to form the 20S particle (9–11). Association with cis-SNARE--SNAP complexes 
triggers ATP hydrolysis which leads to a large conformational change in the protein, with the 
major change occurring at the N-terminus where it folds back over the D1-D2 rings (8). This 
generates enough force to disrupt the 20S complex and separate the individual SNAREs from each 
other effectively reactivating them.  
  
Previous work identified that both NSF and Sec18 bind to the regulatory glycerophospholipid 
phosphatidic acid (PA) (12, 13). PA has been shown to have regulatory effects in multiple vesicular 
trafficking pathways including sporulation, regulated exocytosis, lysosomal maturation, and 
homotypic vacuole fusion (13–17). PA production through phospholipase D activity promotes the 
exocytosis of secretory granules in chromaffin and PC-12 cells (18–21), as well as Glut4 
containing vesicles in adipocytes (22). The ability of PA to promote fusion in these systems is 
attributed to inducing negative membrane curvature (23), bind SNAREs (24, 25), and promote 
hemifusion (21, 26).  
 
PA production however, is not always a positive signal for fusion. In the case of Sec18, increased 
PA levels lead to reduced priming activity likely due to a decrease in recruitment to cis-SNAREs 
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(13). On yeast vacuoles, PA is converted to diacylglycerol (DAG) by the PA phosphatase Pah1, 
an ortholog of mammalian Lipin1. In the absence of Pah1 activity, PA levels remain intact and 
sequester Sec18 from cis-SNARE complexes to prevent priming and arrest the fusion pathway, 
whereas deleting the other PA yeast phosphatases had no effect on fusion (17). DAG can be 
converted to PA through the action of the DAG kinase Dgk1, whose inactivation leads to elevated 
DAG concentrations that enhance fusion through modulating the activity of the Rab GTPase Ypt7 
(27). Thus, the interconversion of PA and DAG serves as a regulatory switch to control vacuole 
fusion.   
  
Here we asked what effects PA-binding has on the overall architectural dynamics of Sec18 that 
could lead to a decrease in its priming activity. To do so, we measured binding of monomeric and 
hexameric Sec18 to different forms of PA. We report that monomeric Sec18 has significantly 
stronger binding than the hexameric form to all forms of PA. We probed changes to the architecture 
of Sec18 when bound to short-chain PA and found that the protein exists in a significantly different 
conformation in its PA-bound state, without significant changes to its secondary structure. To 
study the mechanism of Sec18 binding to PA, molecular dynamics simulations were performed 
using the mammalian version of Sec18, namely NSF.  NSF was used as it has high identity to 
Sec18 and has more structural information available at the protein data bank (PDB ID: 3J94) (28). 
The molecular dynamic simulations performed suggest NSF binds to PA at regions of the protein 
that are only exposed in the monomeric state of the protein. Taken together, we propose that PA 
regulates the priming activity of NSF/Sec18 by limiting the formation of its active hexamer.  
 
RESULTS 
Sec18 monomer binds to PA with higher affinity than the hexameric form – Our previous work 
showed that Sec18 preferentially bound to liposomes containing phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and PA relative to those composed of only PC and PE, or ones 
where PA was replaced with DAG or phosphatidylserine (PS) (13). This was in keeping with older 
findings showing that mammalian NSF bound to resin-linked PA (12). Here our studies were 
extended to further define how Sec18 binds to PA. To start we used microscale thermophoresis 
(MST) to acquire binding affinities to dioctanoyl PA (C8-PA), which prevents Sec18 from binding 
cis-SNARE complexes, consequently precluding priming from occurring (13). We used both 
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monomeric and hexameric Sec18 with a range of C8-PA. The C-terminal 8xHistidine (His8) tag 
of Sec18 was labeled with Ni-NTA Atto 488. As shown in Figure 2.1B, monomeric Sec18 
(mSec18) bound to C8-PA with a KD of 1.4±0.68 µM, whereas the hexameric form (hSec18) had 
a KD of 29±8.6 µM. This suggested that either hSec18 has residues occluded for PA binding or is 
in a suboptimal conformation to efficiently bind C8-PA. It is possible that a small soluble C8-PA 
could access a binding site on Sec18 that is obscured in the hexamer, whereas membranous long 
chain PA is unable to reach PA binding regions on Sec18 hexamers, especially regions contained 
in the hexamerization interface of Sec18 holoenzyme.  
  
Due to the difference in binding affinities to C8-PA, we next asked if limiting the mobility of PA 
to two dimensions would show a similar disparity between the monomer and hexamer. To this aim 
we used extruded 0.8 µm diameter liposomes to approximate the diameter of yeast vacuoles. We 
found that mSec18 bound 0.8 µM liposomes containing 10% long chain PA (80% POPC, 10% 
POPE) with a KD of 29 ± 20 µM while hSec18 bound these liposomes poorly with a KD of 423 ± 
215 µM (Fig. 2.1 C-D). We next used PC liposomes as a negative control and found that hSec18 
bound as poorly as it did to PA liposomes, while mSec18 lacked any detectable interactions above 
the background noise of the system. These findings further establish that hexameric Sec18 lacks 
the ability to bind PA, potentially by masking a binding site or by restricting conformational 
changes needed to bind PA.   
 
Sec18 binding to PA is specific – Our previous work showed that Sec18 binds to vacuoles in a PA 
dependent manner (13). However, others have shown that proteins with PA binding capabilities 
sometimes associate with other anionic lipids including phosphoinositides and phosphatidylserine 
(PS) in a nonspecific, charge dependent manner (29). We previous observed that Sec18 does not 
associate with PS in the membrane, however we wanted to additionally verify that its membrane 
association was not due to highly anionic phosphoinositides. Here we show that Sec18 does not 
readily bind to C8-PI(4,5)P2 (KD ≥ 350 µM) (Fig. 2.1C). This is significant because it was 
previously shown that PI(4,5)P2 is required for SNARE priming to occur at the vacuole (30). Our 




ATP Blocks PA binding by Sec18 – Sec18/NSF like many other AAA+ proteins contains two 
nucleotide binding domains (NBD) each residing in a one of the domains that make up the rings 
of the hexameric protein. The D1 ring of Sec18 hydrolyses ATP to generate the mechanical force 
needed to disrupt cisSNARE bundles whereas the D2 ring binds ATP to stabilize the hexameric 
form of the protein. This is reflected in the different affinities for ATP found between the two 
NBDs. In NSF the D1 NBD binds ATP with a KD of 15-20 µM, while the D2 NBD binds with a 
KD of 30-40 nM (31). Here we asked if ATP binding would affect PA binding. We added 1 mM 
ATP-Mg2+ to binding assays with Sec18 and 0.8 µm PA liposomes. We found that ATP-Mg2+ 
reduced mSec18 biding to PA liposomes while not affecting the already poor binding by hSec18 
(Fig. 2.1D-E). The effect of ATP on mSec18 was possibly due to hexamerization of the protein 
and reduced masking of the PA-binding site. Interestingly, ATP had no effect on the interaction of 
mSec18 and C8PA (Fig. 2.1F). The difference could be due to the close apposition of mSec18 to 
the membrane that affects how ATP alters PA binding, which is not recapitulated in solution.   
  
PA blocks Sec18 binding to Sec17-SNARE complexes – Previously we showed that C8-PA inhibits 
priming activity on isolated vacuoles and by preventing its association with SNAREs. To see the 
direct effect on protein complex formation we used surface plasmon resonance (SPR). Sec18 was 
linked to Ni-NTA sensor chips through its C-terminal 8XHis tag. For these experiments we used 
preassembled soluble SNAREs bundles in which the trans-membrane domains were deleted from 
Vam3, Vti1 and Nyv1. The soluble SNAREs were mixed with the naturally soluble SNARE Vam7 
to allow for 4-helical bundle formation as described previously (32, 33). Soluble SNARE bundles 
were mixed with recombinant Sec17 and flowed over NiNTA-bound Sec18. This approach showed 
100 response units. However, when C8-PA was added in the mixtures with the SNAREs and 
Sec17, we observed a 50% reduction in response units (Fig. 2.1G). Because SPR response units 
are based on mass, we conclude that PA blocked the assembly of the larger SNARE-Sec17-
sSNARE complex.   
  
Both D1 and D2 domains bind Sec18 – Based on structural predictions for PA binding (see below), 
we hypothesized that Sec18 binds PA using both its D1 and D2 domains. To test this, we compared 
full length Sec18 with domains or protein truncations lacking the N-terminal domain (D1-D2) or 
the D2 domain (N-D1) (Fig. 2.2A). Using SPR, GST-Sec18 constructs were flowed over nanodiscs 
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(ND) containing long chain PC and PE (80:20) or long chain PC, PE and PA (80:15:5). The ND 
were linked to the Ni-NTA chip though the His tags of the membrane scaffold proteins. First we 
tested the known PA-binding domain DEP of the murine protein Dvl2 (34). GST-DEP bound to 
PA-ND with a KD of 18.9±2 µM (Fig. 2.2B). Next we tested binding of full length GST-Sec18 to 
PA-ND and found that it bound with a KD of 2.7±2 µM, illustrating that Sec18 interacted with PA 
as well or better than the bona fide PA binding domain DEP (Fig. 2.2C). To verify that the GST 
tag did not alter the binding of Sec18 to PA, we linked Sec18-His8 to the sensor chip and flowed 
C8-PA. By this approach we measured a KD of 1.4±0.46 µM, illustrating that the GST tag had no 
effect on PA binding (Fig. 2.2D). In parallel we tested the D1-D2 construct, lacking the Nterminal 
domain, and found that it bound PA with nearly identical affinity (KD, 1.2±0.4 µM) to full length 
Sec18.  Because the Sec18 N-domain has a polybasic surface at its Sec17 binding site, we tested 
if it also bound to long chain PA. We found that the N-domain bound poorly to PA-ND with a KD 
of 31.8±3.7 µM and to PC-ND with a KD of 11±1.6 µM (Fig. 2.2E-F). These data suggest that the 
N-domain has no lipid-binding specificity and that the effect of PA on Sec18 is limited to the D1-
D2 domains. Next, we used MST to verify our SPR data and to further examine PA binding by 
various constructs. In Figure 2.2G, we show that full length Sec18 bound C8-PA with a KD of 
0.927±.161 µM, which was similar to the value we observed with SPR. We next tested the 
individual domains. The individual D1 and D2 domains bound PA with a KD values 1.5±.35µM 
and 2.96±.55µM, respectively, which is near to what we saw with the D1-D2 construct. In 
comparison, the N-D1 construct bound PA poorly relative to the D1 construct. This suggested that 
the N-domain could sterically interfere with PA binding or perhaps induce a suboptimal lipid-
binding conformation in D1 that does not occur in the full length protein.   
  
Phosphatidic acid alters the conformation of Sec18 Our data thus far suggests that Sec18 
undergoes conformational changes that allow mSec18 to bind PA while hSec18 lacks the ability 
to bind the lipid. To further probe for conformational changes to Sec18 we tested whether PA 
significantly alters binding of 8-Anilino-1-naphthalenesulfonic acid (ANS) to mSec18. ANS is a 
dye that has been extensively used to test lipid-binding proteins because it associates with solution 
exposed hydrophobic motifs (35, 36). Binding of ANS to a protein results in an increase in 
fluorescence yield and a blueshifted emission. Because we have previously seen PA binding to 
mSec18 we expected ANS to also bind the protein in our assay. As expected, we observed ANS 
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binding to mSec18 in a dose-dependent fashion (Fig. 2.3A-B). We next wanted to test for any 
conformational changes upon PA binding that altered ANS binding to Sec18. To do this, we 
titrated increasing amounts of C8-PA into our assay and measured changes in the ANS 
fluorescence spectra. Because C8-PA is partially hydrophobic, ANS was first incubated with each 
lipid concentration to obtain a background spectrum before protein was then added to the assay, 
and fluorescence was again measured. The difference spectra from these measurements shows that 
addition of C8-PA increases the binding of ANS to Sec18 (Fig. 2.3C and 2.3F). To confirm that 
the changes in ANS fluorescence were specific to PA binding, we tested the addition of DAG, the 
product of Pah1 activity on PA. No change in ANS fluorescence was detected in the presence of 
C8-DAG, which is consistent with inability of Sec18 to bind to DAG (Fig. 2.3D and 2.3F). We 
also tested the anionic lipid phosphatidylserine (PS). Similar to what we observed with DAG, the 
addition of C8-PS had no effect on ANS fluorescence (Fig. 2.3E and 2.3F). Together these data 
suggest that C8-PA binding to Sec18 results in a conformational change in the protein that exposes 
additional hydrophobic pockets to solution. Such a change may account for the differences 
previously seen in Sec18 priming activity and cis-SNARE association (13).  
  
To further probe for conformational changes to Sec18 induced by PA we utilized a limited 
proteolysis assay. Proteins can exhibit differences in their proteolytic cleavage profiles when 
bound to a ligand that significantly changes their overall architecture (35). Because we observed 
an increase in solution exposed regions of Sec18 in the presence of PA, i.e. increased ANS 
fluorescence, we expected to also see an increased sensitivity to protease degradation in the same 
conditions. To measure this, mSec18 was incubated with increasing concentrations of trypsin with 
and without C8-PA addition. As expected, mSec18 sensitivity to trypsin degradation increased in 
the presence of C8-PA, whereas the presence of DAG had no effect (Fig. 2.4A-B).   
  
Additionally, we performed the same limited proteolysis assay using thrombin in place of trypsin. 
Thrombin displays much higher specificity than trypsin and should only cleave proteins at specific 
recognition sites. Incubation of Sec18 with thrombin alone showed no proteolytic degradation of 
the protein indicating that no recognition sites were accessible to the protease. However, upon 
addition of C8-PA thrombin was able to cleave Sec18 (Fig. 2.4C-D). Once again, inclusion of C8-
DAG did not show a similar effect indicating once again that the observed conformation change 
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was PA specific. Finally, we titrated C8-PA into a thrombin cleavage assay keeping the 
concentration of the protease constant. Cleavage of Sec18 by thrombin showed dose dependence 
for C8-PA (not shown). These data illustrate that C8-PA binding to Sec18 alters the conformation 
of the protein allowing for the exposure of an otherwise shielded thrombin recognition site. Sec18 
has one predicted thrombin recognition site (after R638) which is located in the D2 domain of the 
protein [exPASy]. The D2 domain is responsible for the multimerization of Sec18 to its active 
hexamer when it is in a nucleotide bound state (37, 38). This further suggests that PA alters the 
conformation of the Sec18 D2 domain, or potentially the conformation of D2 with respect to D1 
allowing binding to PA. Changes to the D2 domain structure could alter nucleotide binding or 
disrupt key interactions between protomers thereby decreasing Sec18 hexamer formation. Sec18 
is known to associate with cis-SNAREs in its active hexameric form, so inhibition of hexamer 
formation could decrease its ability to properly recruit to inactive SNARE complexes. This idea is 
consistent with previous observations that showed increased PA at the vacuole led to decreased 
recruitment of Sec18 to cis-SNARE complexes (13).   
  
Phosphatidic acid has no significant effect on the secondary structure of Sec18 – Because we 
observed significant changes in the conformation of Sec18 upon binding to C8-PA we next wanted 
to monitor changes in the secondary structure of the protein when bound to the lipid. To do this 
we observed the α-helix and β-sheet content of Sec18 in the presence of PA using circular 
dichroism (CD). CD spectra of mSec18 were obtained in the absence and presence of C8-PA to 
determine if the protein’s secondary structure was significantly affected by binding the lipid. The 
CD spectrum obtained for mSec18 alone showed that the protein was well folded (Fig. 2.4E). 
Upon addition of C8-PA, no significant changes were seen in the spectrum suggesting the lipid 
binding does not alter secondary structure features within the protein.   
  
To rule out any denaturation caused by binding of C8-PA to Sec18, intrinsic tryptophan 
fluorescence was measured with and without lipid addition. Sec18 contains three tryptophan 
residues (W88, W91, and W632) in its N and D2 domains. Upon denaturation of Sec18 with SDS, 
Trp fluorescence was red-shifted and showed decreased intensity (Fig. 2.4F). Upon incubation 
with C8-PA, no shift or intensity change was observed. This suggests that PA binding to Sec18 
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did not lead to denaturation, i.e. causing a conformational change large enough to alter the local 
environment of any of the Trp residues found in the protein.   
  
Finally, to test whether binding PA altered the thermal stability of Sec18, we used differential 
scanning fluorimetry (DSF) (39). Sec18 was labeled with SYPRO orange dye, incubated with 
different concentrations of C8-PA in separate wells, and equilibrated prior to starting a melting 
curve. Fluorescence was scanned across a temperature gradient of 20 to 95°C and the first 
derivative of the fluorescence data was used to determine the Tm for each condition. DSF has the 
ability to show multiple melting transitions (40, 41). Our data show that mSec18 has three melting 
transitions. The first mSec18 transition (TM1) occurred at ~45°C, while TM2 and TM3 were at 60°C 
and 64°C, respectively (Fig. 2.4G). The addition of C8-PA had no effect on TM2 and TM3, as the 
curves overlapped with the that of apo-Sec18. That said, C8-PA has a striking effect at TM1 where 
we observed a dose-dependent increase in fluorescence. This likely mirrors the conformational 
changes seen with limited proteolysis and ANS fluorescence. Taken together these observations 
lead us to conclude that PA binding to Sec18 induces a significant change to the architecture of 
the protein but does not denature the protein nonspecifically.  
  
NSF D1-D2 undergoes large conformational change during transition between hexameric and 
monomeric forms – To examine the Sec18 conformational changes we observed previously at a 
more detailed level, atomic molecular dynamics (MD) simulations were performed using NSF, the 
mammalian homolog of Sec18. The NSF D1-D2 monomer extracted from the cryo-EM structure 
of an ATP-bound NSF complex (pdb 3J94) after removing bound ATPs was equilibrated with 
restraints for 20 ns and then relaxed for 200 ns (Video S1). Based on the overall alpha carbon (Cα) 
RMSD, the monomer undergoes conformational changes up to 15 Å apart from the form originally 
adopted in the hexamer (Fig. 2.5A). Calculation on the secondary structure components showed 
that only the modeled loop region from residue 458 to 478 transitioned from helix during the 
relaxation to turn and coil (data not shown). This is expected as the loop was poorly resolved in 
cryo-EM and was only stabilized by interactions with the N-domain in the template crystal 
structure (the N-D1 domain of p97) used in homology modeling. The stable secondary structure 
observed in D1 and D2 domains indicated that the large deviation did not come from secondary 
structural changes, further verifying CD experiments. Instead, we observed that the conformational 
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change was accompanied by an opening-up process of D1 and D2 domains during the relaxation. 
The observation was in agreement with the hypothesis that NSF hexamerization might require 
certain conformations of D1-D2 monomer and that the conformation required could be further 
stabilized at the hexamer interface. Figure 2.5B shows the equilibration of individual protomers 
in a NSF hexamer. These data indicate that the hexamer is more stable (Video S2).  
  
Residues of NSF shown to bind to C8PA are not available for PA binding when it is in the 
hexameric form – Computational flooding studies were performed for both monomeric and 
hexameric form of the NSF D1-D2 domains, based on the structural information of mammalian 
NSF (Fig. 2.6A). The binding affinity of each amino acid residue was analyzed using percent 
bound as determined by the fraction of time when PA lipids found in proximity (minimal distance 
between phosphate group atoms of PA and the amino acid residue below H-bond distance). 
Residues determined to have highest percent bound were determined for both monomeric and 
hexameric forms of D1-D2. Our flooding simulations of NSF hexamer showed that residues having 
the highest percent bound PA in the monomer (Fig. 2.6B) were shielded to block lipid binding in 
the hexameric NSF D1-D2 construct (Fig. 2.6C).  This suggests that PA binding specificity lies 
somewhere within the hexameric interface.   
  
Binding Prediction and Clustering Analysis of PA Binding Regions of NSF – Ensemble molecular 
docking of C8-PA to NSF monomer was performed using the aforementioned D1-D2 equilibrium 
simulation (42). Snapshots from the equilibrium trajectory were utilized for molecular docking 
every 100 ps to fully sample conformational dynamics. The resulting docked C8-PA poses were 
clustered (43) and an average Autodock Vina scoring function scores were determined for the 
clusters of monomeric NSF. These scoring function results show some correlation with the MST 
binding measurements of mSec18 and hSec18 to C8-PA (44) (Fig. 2.7A & 2.7E). To further verify 
the cluster analysis, a SiteMap analysis was performed and the and the top three sitescores were 
chosen (Fig. 2.7D).  Both figure 6A and 6D indicate affinity to two main regions of Sec18, mainly 
in the interface of D1 and D2, as well as a significant affinity to the D2 ATP binding site (Fig. 
2.7B-C). Furthermore, to fully evaluate the potential PA binding sites of Sec18, the hexameric 
form was also surveyed, using the same methodology as the monomer. The results showed a 




Molecular Dynamics of NSF bound PA May Indicate a Hinge Mechanism – Molecular dynamics 
simulations were selectively performed on clusters 3 and 4 (purple and orange), which are found 
in the interface between D1 and D2, not overlapping with the D2 ATP binding site. From each of 
the two clusters a top pose was filtered using the highest Autodock Vina scoring function score for 
simulation (Videos S3 and S4). These simulations indicate flexibility between the D1-D2 interface 
(Fig. 2.8). These simulations show either an opening of closing of D2 with respect to D1 as 
demonstrated by overlapping trials. These results further support the mechanism as described in 




Membrane fusion is a necessary process for all eukaryotes, and Sec18/NSF is the only known 
protein responsible for utilizing energy from ATP to prime SNAREs (3, 4, 8). To achieve 
compartmental specificity, unique SNARE combinations are utilized by defined organelles as well 
as smaller transport vesicles budding from such organelles (45). Each organelle varies in both size 
and function, and must contain its own unique combination of protein and lipid factors to allow 
for specificity in trafficking and membrane fusion events. Regulation of Sec18/NSF is of special 
significance due its direct role in maintenance of fusion and compartmentalization throughout the 
eukaryotic cell. Therefore, it is important to understand the role that regulatory factors have on 
ubiquitous fusion machinery such as Sec18/NSF to adequately model how specificity and 
efficiency are balanced and maintained at different locations in the cell.  
   
Protein function can be regulated directly through posttranslational modifications or through their 
interactions with other molecules, including lipids. The vacuole fusion pathway is regulated at 
various stages by distinct lipids such as phosphoinositides, ergosterol, DAG and PA (13, 17, 27, 
30, 39, 46– 52). The priming stage requires the presence of ergosterol, PI(4,5)P2, as well as the 
conversion of PA to DAG (13, 17, 30, 49).  
  
Previously we found that vacuolar PA sequestered Sec18 from cis-SNAREs and that the PA 
phosphatase Pah1/Lipin1 was required to convert PA to DAG to allow Sec18 dissociation from 
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the membrane and recruitment to SNARE complexes (13). We should also reiterate that the other 
yeast PA phosphatases have no effect on vacuole fusion, illustrating that this regulation is specific 
for Pah1 function.  Although PA turnover is needed for priming, the presence of the lipid is also 
required downstream for mechanisms that remain to be characterized. Deletion of PAH1 or the 
DAG kinase DGK1 alters the balance of PA and DAG on vacuole to dramatically affect membrane 
fusion (17, 27). We thus postulate that enzymatic changes that alter PA levels can in turn shift the 
equilibrium of Sec18 from a lipid-bound to a to a SNARE-associated state. Such changes would 
likely have significant effects on SNARE disassembly and the overall progression of the 
membrane fusion cascade. That said, any membrane where PA is lacking would be expected to 
have unfettered access Sec18 to SNAREs.  
  
In this study we demonstrated that Sec18 directly binds PA with high affinity on par with a known 
PA-binding domain. Moreover, only monomeric Sec18 could bind both long chain PA in 
membranes and soluble C8-PA, whereas hexameric was only able to bind C8-PA. This signifies 
that C8-PA could access PA-binding residues that are blocked in the hexamer to prevent membrane 
association. Our findings indicate that Sec18 may exist in both a monomeric lipid-bound pool and 
SNARE-bound hexamers. Because ATP is required for Sec18 hexamerization, we tested PA 
liposome binding in the presence of ATP. PA-liposome binding by Sec18 was blocked by ATP. 
We posit that mM ATP concentrations may shift the monomeric pool of Sec18 used to a hexameric 
pool decreasing its affinity for PA. It is worth noting that ATP concentrations in the cytoplasm 
have been measured in the low millimolar range which would likely promote spontaneous hexamer 
formation and maintenance at the vacuole membrane (53). This would suggest Sec18 almost 
always exists as an active hexamer under physiological conditions. However, we have previously 
observed disruption of Sec18 activity upon a shift to high levels of PA at the vacuole even in the 
presence of millimolar concentrations of ATP (13, 17). Additionally, Sec18 association with the 
vacuole membrane is maintained throughout the fusion cycle, even after it hydrolyzes ATP and 
allows for the release of Sec17 from the membrane (3). Sec18 binding to the vacuole is also 
required for membrane association of the fusion factor LMA1, even in the absence of ATP (54). 
These findings agree with our results and suggest Sec18 may associate with the vacuole membrane 
in a nucleotide free state. It is however unclear whether some unknown interaction between Sec18 
and a fully functional vacuole would limit, or regulate, ATP binding prior to its release upon Pah1 
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activity. Given our results and these previous findings, we hypothesize that PA at the vacuole 
membrane stabilizes a nucleotide free, monomeric form of Sec18 before its recruitment to cis-
SNAREs. Our evidence for this, however, is indirect and future work should aim to investigate the 
presence of a monomeric form of Sec18 in vivo.  
  
During priming, Sec17/α-SNAP is recognized by Sec18/NSF in an ATP bound state at D1 before 
subsequent ATPase activity occurs. We think that Sec18 exists in both lipid-bound and 
SNAREbound states and that the presence of ATP at the D1 NBD may determine the state in which 
the protein primarily exists. Membrane PA may prevent the association of ATP with the D1 NBD 
locking the protein in an inactive lipid-bound state preventing recruitment to inactive SNARE 
complexes. This is in line with our data in this study and with observations from previous work 
(13).  
  
The fact that Sec18 monomer binding to PA liposomes was inhibited at a saturating ATP 
concentration for the D1 NBD could indicate that the PA binding site for Sec18 lies near the D1 
ATP binding site. Alternatively, it is possible the conformation of Sec18 in its ATP bound state 
shields the protein’s unique PA binding site. The idea that Sec18 binding to PA may not 
specifically depend on the D1 ATP binding site was supported by computational flooding 
experiments performed on both hexamer and monomer in the presence and absence of ATP. 
Flooding experiments allowed for C8-PA to equilibrate with NSF monomer, and binding was 
measured using the length of time a PA molecule resided near a given residue of NSF. Many of 
the long term amino acid residues sharing the longest contact time to PA were predictably basic 
residues, especially lysine and arginine. However, dramatic differences in these residues were not 
noticed between the ATP and non-ATP simulations. Furthermore, many of the residues with longer 
PA binding time were not of importance for PA binding in the hexamer simulation. This result is 
in corroboration with the high binding affinity of Sec18 monomers to PA liposomes vs the 
hexameric form. This further indicates that the Sec18 monomer and hexamer are differentially 
regulated. Furthermore, it suggests that PA may influence the formation of the active hexamer by 




We propose that Sec18/NSF PA regulation is achieved by sequestration of its protomers by PA to 
block the formation of the active hexamer to prevent unchecked priming. Upon binding PA, 
Sec18/NSF undergoes a significant conformational change that coincides with a reduction in its 
SNARE priming activity. Thus, PA sequestration can negatively regulate SNARE priming (55).  
Additionally, it is possible that PA at the site of priming could have a globally positive influence 
on priming by increasing the local concentration near the site of action. Previous work has shown 
that PA is necessary for vacuole fusion to occur and is required for Sec18 association with the 
membrane (56). While this appears to somewhat contradict our findings presented here, we do not 
believe this is the case. Unregulated Sec18 activity has previously been shown to be detrimental 
to vacuole fusion (57–60).  Factors such as the PA phosphatase Pah1/Lipin, could thus serve to 
activate Sec18/NSF only once its activity was required (13, 17). In this way, PA could serve as a 
temporal regulator of SNARE priming activity and of the membrane fusion process as a whole. It 
is also likely that PA membrane concentrations could differentially affect organelles with distinct 
lipid content. Depending on the concentration and localization of PA at a given membrane Sec18 
sequestration by PA could either play a larger or less prominent role in regulating the priming of 
SNAREs.   
  
Based on our computational studies, it appears that there are numerous candidate residues that 
might contribute to Sec18 PA binding. Membrane simulations have been performed (data not 
shown); however, due to the size and flexibility of Sec18 monomer, long time scales in the micro 
second range may be required to show final binding events sequestering Sec18 to a PA containing 
membrane. We plan to further probe this binding event using membrane simulations at longer time 
scales to capture the exact binding event of Sec18 to a PA membrane, and to specifically identify 
the numerous residues that may be involved.    
  
Because NSF binds PA, we assume that the results from yeast Sec18 will translate to the 
mammalian system. Our computational results using NSF indicate a conformational change in a 
novel region of NSF that would not be expected merely from the function of D1 ATPase activity 
on the N-domain. Our model suggests that PA may influence the ability for NSF to both localize 
and polymerize, in order to form an active hexameric priming complex. This priming complex 
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could then be differentially regulated at a given organelle utilizing PA as a regulatory lipid, as 
indicated by our studies of Pah1 at the vacuole (17).  
  
 
MATERIALS AND METHODS 
  
Reagents – POPA (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate), POPC (1-palmitoyl-2-oleoyl-
snglycero-3-phosphatidylcholine), POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphatidylethanolamine), C8-PA (1,2-dioctanoyl-sn-glycero-3phosphate), C8-DAG (1,2-
dioctanoyl-sn-glycerol), and C8-PS (1,2-dioctanoyl-sn-glycero-3-phosphoL-serine) were 
purchased from Avanti Polar Lipids (Alabaster, AL, USA) as chloroform stock solutions and 
stored at -20°C. CM7 and Ni-NTA (Standard and S series) sensor chips, and Regeneration buffers 
(Glycine pH 1-3) were procured from GE Healthcare (Buckinghamshire UK). Ni-NTA  
Atto 488 dye was procured from Sigma-Aldrich Corp. (St. Louis Missouri). Monolith NT.115 
standard treated capillaries for thermophoresis were purchased from Nanotemper (München 
Germany).   
  
Plasmid construction –Plasmid for expression of Sec18-His8 was created by amplification of 
SEC18 by PCR from genomic DNA of the yeast strain DKY6281 using primers containing NdeI 
and XhoI restriction cut sites (Forward: 5’-ACGTACGTCATATGTTCAAGATACCTGGT 
TTTGG-3’, Reverse: 5’-ATCGAATGCTCGAGTGCGGATTGGGTCATCAACT-3’). PCR 
Product was inserted into pET42a using NdeI and XhoI in frame with a C-terminal 8xHis tag 
sequence under the control of a T7 promoter to create pSec18H8.  
  
Plasmid for expression of GST-Sec18 was created using primers containing EcoRI and XhoI 
restriction cut sites (Forward: 5’-ATGCAATGGAATTCATGTTCAAGATACCTGGTTTTGG-
3’, Reverse: 5’-ATCGAATGCTCGAGTTATG CGGATTGGGTCATCAACT-3’). PCR product 
was inserted into pParallel GST using EcoRI and XhoI to create pGSTSec18. Plasmid for 
expression of GST-N terminal domain was created in the same way using a different reverse 
primer (Forward: 5’-ATGCAATGGAATTCATGTTCAAGATACCTGGTTTTGG-3’, Reverse: 
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5’-ATCGAATGCTCGAGTCTTCCTTTGAAAAAATTAATTTGTGTTTGTTT-3’) to create 
pGSTN.  
  
Protein purification – For purification, pSec18His8 was transformed into Rosetta 2 (DE3) pLysS 
Competent Cells (Novagen) and Sec18-His8 expression was carried out using auto-inducing 
medium (AIM) (61). Cells were grown in AIM until reaching stationary phase (37°C, 18 h, 
shaking) and harvested by centrifugation. Cells were resuspended in lysis buffer (20 mM HEPES 
pH 6.8, 300 mM NaCl, 0.1% Triton-100, 2 mM 2-mercaptoethanol, 20 mM imidazole, 10% 
glycerol, 1 mM ATP, 1 mM PMSF, and 1X cOmplete Protease Inhibitor Cocktail (Roche)) and 
lysed by French press. Lysates were cleared by centrifugation (50,000 x g, 20 min, 4°C) and 
incubated with Ni-NTA resin (Invitrogen) overnight at 4°C. Resin was washed with 100 bed 
volumes of wash buffer (lysis buffer with 50 mM imidazole) before protein was eluted in 1 ml 
fractions (lysis buffer with 250 mM imidazole). Protein was concentrated before being run 
through gel filtration (Superose 6) using size exclusion buffer (20 mM HEPES pH 6.8, 300 mM 
NaCl, 1 mM 2-mercaptoethanol, 10% glycerol). Sec18-His8 elutes in two peaks corresponding 
to monomeric and hexameric pools. Each pool was collected and concentrated before use. For 
circular dichroism experiments, Sec18-His8 was purified using the same approach with different 
buffer compositions. CD lysis buffer (50 mM phosphate buffer pH 6.8, 20 mM imidazole, 1mM 
PMSF), CD wash buffer (50 mM phosphate buffer pH 6.8, 50 mM imidazole), CD elution buffer 
(50 mM phosphate buffer pH 6.8, 250 mM imidazole), and CD SEC buffer (50 mM phosphate 
buffer pH 6.8) were used. GST-Sec18 was purified similarly using Rosetta 2 (DE3) pLysS 
Competent Cells transformed with pGSTSec18 but with the following changes. GST lysis buffer 
(50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM ATP, 1 mM PMSF, and 1X cOmplete 
Protease Inhibitor Cocktail) was used through the lysis and chromatography wash steps. Protein 
was eluted with GST elution buffer (20 mM HEPES pH 7.2, 150 mM NaCl, 10 mM reduced 
glutathione) and dialyzed against 1X HBS pH 7.2 before being aliquoted and stored at -80°C. 
GST-N was purified in the same way using cells transformed with pGSTN. The DEP PA binding 
domain from murine Dvl2 was purified as a GST-fusion as described (34). Membrane scaffold 
protein 1D1 (MSP1D1-His) was prepared as described (62). GST-Vam7 and Sec17 were 
expressed and purified as shown previously (32, 63, 64). Purification of GSTNyv1(DTM), was 
performed as previously described with minor changes (65). Protein overexpression was carried 
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out in E. coli (BL21) using auto-inducing medium (AIM) (61). Cells were grown in AIM until 
reaching stationary phase (37°C, 18 hours, shaking) and harvested by centrifugation. Cells were 
resuspended in lysis buffer (1X PBS pH 7.4, 2mM EDTA, 2mM DTT, 1 mM PMSF, and 1X 
cOmplete Protease Inhibitor Cocktail (Roche)) and lysed by French press. Lysate was cleared by 
centrifugation (50,000 x g, 20 min, 4°C) and incubated with Glutathione Agarose resin (Pierce) 
overnight at 4°C. Resin was washed with 100 bed volumes of lysis buffer before protein was 
eluted in 1 ml fractions (20 mM HEPES pH 7.2, 150 mM NaCl, 20 mM glutathione). Protein was 
concentrated before dialysis in 1X HBS pH 7.2. MBPsVti1 and MBP-sVam3s were purified as 
previously described with minor changes (66). Briefly, protein overexpression was carried out in 
E. coli (BL21) using AIM (37°C, 18 h, shaking). Cells were harvested by centrifugation and 
resuspended in lysis buffer (20 mM Tris pH 8.0, 200 mM NaCl, 1 mM PMSF, and 1X cOmplete 
Protease Inhibitor Cocktail (Roche)). Cells were lysed by French press and lysate was cleared by 
centrifugation (50,000 x g, 20 min, 4°C). Cleared lysate was incubated with amylose resin (New 
England Biolabs) overnight at 4°C. Resin was washed with 100 bed volumes of lysis buffer and 
eluted in 1 ml fractions with elution buffer (lysis buffer with 10 mM maltose). Proteins were 
concentrated and dialyzed into 1X HBS pH 7.2.  
  
Nanodisc Preparation – Lipid composition of PA nanodiscs consisting of 3.023 µmol POPC 
diC16, .098 µmol PA diC16, and .78 µmol POPE and PC nanodiscs consisting of 3.121 µmol 
POPC diC16 and .78 µmol POPE were combined, dried, and desiccated overnight. Lipids were 
then dissolved in 20 mM sodium deoxycholate in TBS (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 
and .02% NaN3) and sonicated. MSP1D1 membrane scaffold protein (MSP) was then added in a 
ratio of 70:1 lipid to protein and detergent removed with Bio-Beads® SM2 (Bio-Rad). Nanodiscs 
were isolated using size exclusion chromatograph and quantified using a NanoDrop and the 
extinction coefficient of 21,000 L mol-1 cm-1 for MSP1D1 (24.66 kD), and the resultant mg/mL 
divided by two because there are two MSP proteins per nanodisc (67).  
  
Surface Plasmon Resonance – Surface plasmon resonance (SPR) measurements were performed 
on a Biacore T200 instrument equipped with an Ni-NTA chip (68). Approximately 2000 RU of 
5% PA nanodiscs were immobilized non-covalently using 100 mM NiSO4 flowed at 10 µL/s 
followed by a blank buffer injection of HEPES pH 7.4, 150 mM NaCl (HBS Buffer). Injections 
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were performed in HBS buffer at a flow rate of 30 µl/min with an association time of 90 sec, 
dissociation time of 300 sec., and binding was measured in relative response units (RU) as 
described (67). Regeneration with EDTA was performed at flow rate 30 µL/s for 120 s using 100 
µM EDTA buffer. Proteins were injected using 1:1 dilutions from highest concentration and steady 
state was obtained using GE BIAcore T200 evaluation software version 3.0 (BIAevaluate). 
Proteins were injected using 1:1 dilutions for Sec18 monomer (3.64 µM, 1,82 µM, 911 nM, and 
455 nM), DEP PA binding domain (57.5 µM, 28.8 µM, 14.4 µM, 7.2 µM, 3.6 µM, 5.8 µM), and 
N domain from Sec18 (84.3 µM, 8.4 µM, 4.2 µM, 1.1 µM, 527 nM, and 1.69 µM) with one 
concentration from each titration run in duplicate. Steady state data was fitted and exported using 
BiaEvaluate software into GraphPad Prism 7.00 for Windows, GraphPad Software (La Jolla, CA).  
  
Microscale thermophoresis – Thermophoresis measurements were performed using a Monolith 
NT.115 labeled thermophoresis machine (69). Sec18-His8 was labeled with Ni-NTA Atto 488 
according to the manufacturer’s protocol mixing 200 nM protein with 100 nM dye and allowing 
to sit at room temperature for 30 minutes followed by centrifugation. M.O. Control software was 
used for operation of MST. Target protein concentrations were 50 nM for all His-tag labeled 
proteins Sec18 monomer, Sec18 hexamer, PA nanodiscs, and PC nanodiscs. LED excitation power 
was set to 90% and MST set to high allowing 3 seconds prior to MST on to check for initial 
fluorescence differences, 25 s for thermophoresis, and 3 s for regeneration after MST off. Analysis 
was performed using M.O. Affinity Analysis Software as the difference between initial 
fluorescence measure in the first 5 s as compared with thermophoresis at 15 s. All measurements 
were performed in PBS buffer (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4, 
pH 7.4) without Tween and binding affinity was generated using Graphpad Sigmoidal 4PL fit from 
points exported from M.O. Affinity Analysis software using KD Model with target concentration 
fixed at 50 nM generating bound, unbound, and fraction bound for export to Graphpad in order to 
estimate final KD.    
  
Limited Proteolysis – Cleavage reactions were carried out in proteolysis buffer (20 mM HEPES 
pH 7.2, 150 mM NaCl, 2 mM ATP, 2 mM MgCl2). Sec18-His8 (2 µM) was added to proteolysis 
buffer and incubated with indicated lipid concentration on ice for 5 min. Trypsin or thrombin 
diluted in 1X HBS was added to assay tubes at indicated concentrations and incubated at 25°C for 
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30 min. Cleavage reactions were stopped with the addition of SDS sample buffer containing 1 mM 
PMSF. Samples were resolved with SDS-PAGE and gels were stained using Coomassie Blue. Gels 
were destained with methanol/acetic acid solution (50%/7%) and imaged using a ChemiDoc MP 
Imaging System (Bio-Rad).  
  
Tryptophan Fluorescence Spectroscopy – Sec18His8 (500 nM) was incubated with the indicated 
concentrations of C8-PA in fluorescence assay buffer (20 mM HEPES pH 7.2, 150 mM NaCl, 1 
mM MgCl2, 1 mM ATP). Lipid dilutions were first prepared in assay buffer and measured for 
background fluorescence before Sec18-His8 was added and incubated at 25°C. Intrinsic 
tryptophan fluorescence measurements were made using a fluorimeter with Peltier temperature 
control (Agilent Technologies). Samples were excited at 295 nm and the emission spectra were 
collected from 300-400 nm. Samples were measured in a 100 µL cuvette (Starna Cells). Initial 
background fluorescence spectra for each lipid concentration were subtracted from final 
measurements.  
  
1,8-ANS Fluorescence Spectroscopy – ANS binding experiments were carried out in fluorescence 
assay buffer with 5 µM 1-anilino-8-naphthalenesulfonate (ANS) (Cayman Chemical). Initial 
spectra were taken without Sec18-His8 to measure any background fluorescence from buffer or 
added lipids (ex. 350 nm, em. 390-620 nm). Sec18-His8 diluted in assay conditions was then added 
to the assay to the indicated concentration and incubated at 25°C for 5 min before spectra were 
obtained. Initial background fluorescence spectra for each lipid concentration were subtracted 
from final measurements.  
  
Circular Dichroism – Monomeric Sec18-His8 purified in phosphate buffer was incubated with and 
without C8-PA to equilibrium (25°C, 15 min). Protein concentration used was 5 µM and lipid 
concentration used was 100 µM. Circular dichroism was measured using a spectropolarimeter 
(JASCO). All spectra were recorded from 260 nm to 200 nm at 50 nm min-1 and measurements 
were taken in a 1 mm pathlength cuvette.   
  
Differential Scanning Fluorimetry – Sec18 (2.75 mg/mL) was diluted to a final concentration of 
0.11 mg/mL in phosphate buffer containing 1 mM ATP, 1 mM MgCl2, and 4X SYPRO orange 
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dye. Next, 22.5 µL of this mix was added to a white hard-shell 96-well PCR plate (Bio-Rad) which 
contained 2.5 µL of serial dilutions of C8-PA in phosphate buffer. The plates were then sealed 
with Microseal ‘B’ film (Bio-Rad), and samples were allowed to equilibrate at room temperature 
for 30 min before beginning the assay. Melting curves were performed using a Bio-Rad CFX 
Connect real-time detection system. The melt curve protocol was 25°C for 3 min followed by a 
25-90°C gradient with 0.5°C increments. Each temperature was held for 10 seconds and the 
fluorescence intensity was measured (Ex = 490 nm, Em = 560 nm). The first derivative of the 
fluorescence readings was used to determine the melting temperature(s) for each condition.  
  
Preparation of D1-D2 monomer and hexamer models – The D1-D2 monomer model (residues 
215737) was derived from an Cryo-EM structure of ATP-bound NSF complex (PDB 3J94 - chain 
A) (8). Missing residues [335-346, 458-478 in PDB 3J94 (chain A)] were built via homology 
modeling using the crystal structure of the homologous N-D1 domain of p97 (PDB 1E32) as a 
template by MODELLER 9.19 (70). The complete D1-D2 hexamer model was prepared (71) using 
the same PDB 3J94 as the monomer. Missing loops in each monomer were modeled in CHARMM 
GUI to ensure that no clashes or topological errors exist in the complex structure. Cis-peptide 
bonds in both monomer and hexamer structures were examined and fixed manually using 
Cispeptide plugin in VMD (72). A further refinement of loops built in the hexamer was performed 
via MDFF (73).  
  
Equilibrium MD simulations of D1-D2 monomer and D1-D2 hexamer – The MD simulations 
were performed with NAMD 2.12 (74) using CHARMM36m force field (75). Langevin dynamics 
and Langevin piston Nosé−Hoover methods (76, 77) were used to maintain constant temperature 
at 310.15 K and pressure at 1 atm. The long-range electrostatic forces were evaluated using the 
particle mesh Ewald (PME) method (78, 79) with a 1 Å grid spacing. The van der Waals 
interactions were calculated with a cutoff of 12 Å and a force-based switching scheme after 10 Å. 
Integration time step was set at 2 fs with SETTLE algorithm (80) applied. VMD 1.9.3 was used 
for MD trajectory visualization and analysis (81). The D1-D2 monomer model was first 
equilibrated for 20 ns with harmonic restraints (0.05 kcal/mol/Å2) on protein Cα atoms except 
modelled loops, then followed by 200 ns equilibration without restraints. Furthermore, the D1D2 
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hexamer was modeled as for D1-D2 monomer, and simulated for 50 ns without restraints, this 
was utilized for ensemble docking of PA.  
  
PA Lipids Flooding Simulations of D1-D2 Monomer and D1-D2 Hexamer – To demonstrate that 
hexamerization of sec18 monomer shields PA binding sites, three independent PA lipids flooding 
simulations were carried out for (1) D1-D2 monomer in the absence of ATP molecules; (2) D1-
D2 monomer in contacts with four ATP molecules taken from the hexamer structure and (3) D1-
D2 hexamer with all bound ATP molecules. Flooding simulations were prepared by first placing 
the protein in a PA lipids grid with a grid spacing of 25 Å, where PA lipids were modeled with 
truncated acyl chains as described in the highly mobile membrane-mimetic model (Qi et al., 2015; 
Vermaas et al., 2017) to reassemble the C8-PA experiments as well as to avoid micelle formation, 
followed by solvation and ionization to a NaCl concentration of 150 mM using the SOLVATE and 
AUTOIONIZE plugins within VMD (81). The two final D1-D2 monomer systems contained 61 
PA lipids in a simulation box of size 95 Å ´ 94 Å ´ 120 Å, while the D1-D2 hexamer system 
contained 223 PA lipids in a simulation box of size 188 Å ´ 187 Å ´ 133 Å, resulting in a similar 
PA lipids concentration (~120mM) in all three systems.  D1-D2 monomer systems were simulated 
for 350 ns each and the hexamer system was simulated for 166 ns, recorded every 20 ps each. 
Harmonic restraints (0.1 kcal/mol/Å2) were applied on protein Cα atoms except for modeled loops 
as well as the ATP molecules throughout the simulation to prevent conformational changes of the 
protein or the disassociation of ATP. The PA binding affinity of each amino acid residue was 
evaluated by calculating the fraction the time that any PA phosphate group atom can be found 
within 3 Å of this residue (hydrogen atoms not included).   
  
Binding Site Probing of NSF for PA – To characterize C8-PA and D1-D2 monomer interactions, 
molecular ensemble docking of PA was done on D1D2 monomer using AutoDock Vina (42). The 
previously mentioned equilibrium simulation of D1D2 was used to fully sample the dynamics of 
D1D2 for molecular docking, where snapshots were taken every 1000 ps of the 200 ns trajectory. 
For each snapshot, an 80Å by 94Å by 108Å grid box was used to fully sample the entire structure. 
Each snapshot was docked with an exhaustiveness of 10, yielding a total of 2000 PA docked poses, 
with the affinities of each poses obtained from the resultant log files. These poses where then 
clustered using a hybrid K-centers and K-medoids clustering algorithm using root-mean-square 
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deviation (RMSD) method (43, 82) for which three main clusters where identified. These clusters 
where then compared to SiteMap (83). Schrodinger SiteMap was used on equilibrated D1-D2 NSF 
monomer indicating top potential ligand binding regions of NSF D1D2 monomer including 
shallow binding sites. The same protocol of ensemble docking of PA was done on the 50 ns 
simulation of hexameric D1-D2, with snapshots taken every 100 ps. A grid box size of 135Å by 
135Å by 135Å with a search exhaustiveness of 10 was used, yielding a total of 5000 PA docked 
poses that were then clustered using the same methodology as the monomer.  
  
MD Simulations of Top Poses From Ensemble Scoring Function – To further probe the effect of 
C8-PA on D1-D2 conformation, MD simulations were performed as for equilibrium simulation 
using both NAMD and CHARMM36m force field.  Poses from each cluster provided by the 
ensemble docking from AutoDock Vina with highest scoring function score were selected for 
simulation. Monomer MD simulations of 100 ns were performed for each of the top poses from 
each cluster in same solvent as for flooding containing 150 mM NaCl in water. VMD was used to 
visualize results and create figures. 
 
Data Analysis and Statistics – Results are expressed were calculated using two-tailed unpaired t-
















Figure 2.1. Sec18 Hexamer and monomer binding affinity for PA. (A) Schematic of Sec18 
monomer and hexamer. Shown is the priming reaction where monomeric Sec18 (mSec18) is 
initially bound to the membrane after which it is released upon Pah1 activity. Released mSec18 
then forms hexameric Sec18 (hSec18) and is recruited to cis-SNARE bundles decorated with 
Sec17. Sec18 hydrolyses ATP to dissociate the SNAREs into individual proteins leading the 
release of Sec17 and the soluble SNARE Vam7. (B) C8-PA MST measurements were performed 
using purified Sec18 monomer and hexamer labeled with Ni-NTA Atto-488 dye at 90% LED and 
High MST using NT.115 Labeled Thermophoresis. Binding affinity was measured using 
thermophoresis at 15 sec mixing separate reactions of half 100 nM Atto 488 labeled Sec18 
monomer and half 1:1 titrations of C8-PA with highest concentration 370 µM according to 
Graphpad Sigmoidal 4PL curve. (C) MST measurements of monomeric Sec18 with C8-PA versus 
C8-PI(4,5)P2.  (D)The effect of 1 mM ATP-Mg
2+ Sec18 binding to liposomes. 800 nm diameter 
extruded PA liposomes (10% PA, 70% PC, and 20% PE) and PC liposomes (80% PC, 20% PE) 
were incubated with Sec18 monomer or hexamer in the presence or absence of ATP. (E) The 
quantitation of multiple experiments run in panel D. Asterisk (*), no measureable PC-liposome 
binding was detected above the background noise of the system. (F) Surface plasmon resonance 
(SPR) of ATP competition of soluble C8-PA biding to Sec18. (G) SPR of Sec18-His8 bound 
toNi-NTA sensor chips. Soluble SNARE complexes (167 µM) (lacking transmembrane domains) 
decorated with µM Sec17 at a 3-to-1 ratio were flowed over the bound Sec18 in the presence or  
absence of 1.25 µM C8-PA. n≥3 for all data shown  
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Figure 2.2. Sec18 Binding Affinity Compared to DEP PA Binding Domain for PA Nanodiscs. 
(A) Schematic of Sec18 constructs and nanodiscs containing PC:PE:PA (80:15:5) (PA-ND) or 
PC:PE (80:20) alone (PC-ND). Red bands depict the membrane scaffold proteins, while the gray 
represent the lipid bilayer. The blue spheres symbolize the presence of PA. (B) GST-DEP was 
flowed over PA-ND attached to a Ni-NTA chip using a BIAcore T200 with a flowrate of 20 µL/s. 
The steady state fit was exported from BIAevaluate software to GraphPad at 4 seconds before 
injection stop set at 90 s with disassociation of 120 s. (C) SPR analysis of GST-Sec18 monomer 
with PA-ND. (D) SPR of Sec18-His8 or D1-D2-His8 bound to a Ni-NTA chip with C8-PA. (E) 
SPR analysis of GST-N-domain with PA-ND. (F) SPR analysis of GST-N-domain with PC-ND. 
(G) MST performed with mSec18, N-D1, D1-D2, D1, and D2 constructs. The His8 tags were 
labeled with 100 nM Ni-NTA Atto 488 labeled and binding was measured using 90% LED and 
60% MST. M.O. Affinity analysis software was used and thermophoresis exported at 15 s. n=3 for 





Figure 2.3. C8-PA acid alters the binding of 1,8 ANS to Sec18. Increasing concentrations of 
Sec18-His8 were incubated with ANS (5 µM) in assay buffer and a representative fluorescence 
spectrum (ex. 390, em. 400-600 nm) is shown (A). Relative fluorescence at 460 nm (B). Sec18-
His8 (0.5 µM) was incubated with increasing concentrations of short-chain lipids in the presence 
of ANS (5 µM) and fluorescence spectra were taken. A representative spectrum for each lipid 
tested is shown: C8-PA (C), C8-DAG (D), and C8-PS (E). (F) Maximum fluorescence for each 
lipid concentration was normalized against overall maximum fluorescence (100 µM C8-PA) for 






Figure 2.4. C8-PA alters the proteolytic cleavage profile of Sec18, but does not affect 
secondary protein structure. Sec18-His8 was incubated with C8-PA, C8-DAG, or alone before 
incubation with increasing concentrations of trypsin (A) or thrombin (C). Densitometry values of 
the un-cleaved band were measured for each concentration and normalized against the input lane 
for trypsin (B) and thrombin (D). Deg., degradation products. (E) Circular dichroism spectra were 
measured (260 to 200 nm, 50 nm min-1) for Sec18His8 in the presence and absence of C8-PA 
(100 µM). (F) Intrinsic tryptophan fluorescence was measured with Sec18-His8 (500 nM) 
incubated with increasing concentrations of C8-PA and fluorescence spectra were measured (ex. 
295, em. 300-400 nm). The fluorescence (em. 333 nm) for each concentration tested was 
normalized against the no lipid control and is shown. SDS (0.25%) was used as a control for 
changing tryptophan fluorescence upon loss of secondary structure. (G) Differential scanning 
fluorimetry first derivative melting curves were measured (SYPRO orange: ex. 490, em. 560 nm) 
for increasing concentrations of C8-PA. n=3 for all data shown. Mr, relative molecular mass 








Figure 2.5. Computational Simulations Show Large Scale Conformational Change Between 
D1 and D2 Subunits of NSF and Indicate Potential PA binding Regions of NSF. (A) D1-D2 
monomer undergoes large conformational change during relaxation. In the first 20 ns, D1-D2 
monomer was equilibrated with a 0.05 kcal/mol/Å2 harmonic restraint on protein Cα atoms. Blue: 
D1-D2 monomer Cα RMSD; green: center of mass distance between D1 and D2 domains. (B) D1-
D2 RMSD of individual protomers within a hexamer are stable throughout equilibration.   
  



















C α  RMSD 
D1-D2 COM distance 
125150175200225 
Time (ns) 





Figure 2.6. Flooding of Sec18 with PA. (A) Protomer chain-A from hexamer cryo-EM structure 
(PDB: 3J94) was simulated in short-tailed PA solution (119 mM, 61 PA molecules in a 95Å x 94Å 
x120Å water box) for 350 ns with ATP binding and 200 ns without ATP. Binding percentages 
were measured according to amount of time a PA molecule was within a hydrogen bonding 
distance from a given amino acid residue of NSF according to heat map on right side of Figure 6A 
with residues of NSF indicated on the X axis and model flooded on Y axis. Both monomer (B) and 
hexamer (C) are shown with key residues from Fig. 6B indicated on Fig. 6B monomer and Fig. 
6C hexamer demonstrating region of hexamer where residues of monomer showing high binding 








Figure 2.7. Ensemble Molecular Docking and Binding Site Prediction of NSF D1-D2 
Monomer. (A) VMD generated image of NSF monomer of D1 (green) and D2 (blue) with space 
filling modeled top clusters ranked in order of highest docking frequency depicted in red, gray, 
purple, and orange, with clusters determined from analysis of AutoDock Vina results. (B) 
Schrodinger SiteMap results of top three sitescore sites of Schrodinger generated image of NSF 
monomer D1 (green) and D2 (blue). (C) VMD generated image as in Fig. 6A including ATP 
aligned into ATP binding sites of D1 and D2 domains. (D) Schrodinger generated image as in Fig. 
6B including ATP aligned as in Fig. 6C. (E) VMD generated image of NSF hexamer as in Fig. 6A 
including autodock generated cluster analysis. (F) Schrodinger generated image of NSF hexamer 













Figure 2.8. Short chain PA MD Simulations. (A) Two separately performed MD simulations 
based on top poses for two clusters determined from ensemble docking and cluster analysis as in 
Fig. 6A-B. MD simulations of each cluster were performed for 100 ns and depicted are two both 
the starting and ending poses of these simulations extracted from Videos S3 and S4. The combined 
finishing poses were aligned to D1 of each D1-D2 NSF monomer and the final Overlapped Trials 
image depicts two separate resting places for the D2 monomer with respect to the D1 monomer in 
response to short chain PA.  
  











Figure 2.9. Model. A Proposed model of mSec18 protomers bound to PA-rich membranes and 
preventing the formation of functional Sec18 hexamers needed for SNARE priming. Binding PA 
causes a conformational change in the protomers between the D1 and D2 domains to stabilize 
membrane association. The PA phosphatase Pah1 hydrolyzes PA to diacylglycerol leading to a 
conformational reversion that is compatible to dissociation from the membrane and incorporation 
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CHAPTER 3: Probing Fusion Priming Regulation by Phosphatidic Acid Through 




The homeostasis of most organelles requires membrane fusion mediated by soluble NSF 
attachment protein receptors (SNAREs). SNAREs undergo cycles of activation and deactivation 
as membranes move through the fusion cycle. At the top of the cycle, inactive cis-SNARE 
complexes on a single membrane are activated, or primed, by the hexameric ATPase associated 
with diverse cellular activities (AAA+) protein, N-ethylmaleimide–sensitive factor (NSF/Sec18), 
and its co-chaperone αSNAP/Sec17. Sec18-mediated ATP hydrolysis drives the mechanical 
disassembly of SNAREs into individual coils, permitting a new cycle of fusion. Previously, we 
found that Sec18 monomers are sequestered away from SNAREs by binding phosphatidic acid 
(PA). Sec18 is released from the membrane when PA is hydrolyzed to diacylglycerol (DAG) by 
the PA phosphatase Pah1. Although PA can inhibit SNARE priming, it binds other proteins and 
thus cannot be used as a specific tool to further probe Sec18 activity. Here, we report the discovery 
of a small-molecule compound, we call here IPA (Inhibitor of Priming Activity), that binds Sec18 
with high affinity and blocks SNARE activation. We observed that IPA blocks SNARE priming 
and competes for PA binding to Sec18. Molecular dynamics simulations revealed that IPA induces 
a more rigid NSF/Sec18 conformation, which potentially disables the flexibility required for Sec18 
to bind to PA or to activate SNAREs. We also show that IPA more potently and specifically 
inhibits NSF/Sec18 activity than does N-ethylmaleimide (NEM), requiring the administration of 
only low µM concentrations of IPA, demonstrating that this compound could help to further 
elucidate SNARE priming dynamics. 
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competitive inhibitor of phosphatidic acid binding by the AAA+ protein NSF/Sec18 blocks the SNARE-priming 
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Eukaryotic life requires membrane fusion, which is integral to numerous processes involved in 
cellular homeostasis and distribution of biological molecules. The terminal catalysts of membrane 
fusion are SNARE (soluble NSF attachment protein receptor) proteins, adding specificity between 
membranes destined to fuse resulting through SNARE compatibility (1). SNAREs interact in trans 
(between two membranes) to form parallel four-helix bundles capable of generating the energy 
needed to merge two membranes into a continuous bilayer. After a fusion event, SNAREs remain 
as inactive cis-SNARE complexes on this newly formed single bilayer. These complexes need to 
be disassembled so that a new cycle of fusion may occur. SNAREs are activated, or primed, by 
the AAA+ protein NSF/Sec18 (Fig. 3.1A). Sec18 is composed of three domains. The N-terminus 
forms the cap domain while the D1 and D2 nucleotide binding domains form the two rings of the 
hexameric complex. Both D1 and D2 domains contain ATP binding sites, however, the hydrolysis 
of ATP by D1 generates most of the energy necessary to disassemble inactive SNARE bundles, 
while the D2 ring binds ATP to stabilize the homo-hexamer (2).  
  
During activation, Sec18/NSF associates with SNARE complexes through binding the adaptor 
protein Sec17/a-SNAP that aids in disrupting SNARE complexes into active individual proteins 
(3). Direct regulation of Sec18/NSF activity remains mostly unknown, although protein kinase C 
(PKC) has been implicated in negative regulation of NSF association with SNARE complexes (4).  
  
Currently, there are two methods of inhibiting priming in vitro. Sec18 can be blocked with an 
antibody or covalently modified with the alkylating agent Nethylmaleimide (NEM), both of which 
inhibit the ATPase activity of Sec18/NSF (5). The exact mechanism by which alkylating with 
NEM affects priming is unclear and not specific. To illustrate, the inhibition of fusion by NEM 
requires a higher concentration than what is needed to inhibit NSF alone, suggesting the presence 
of multiple NEM-sensitive factors involved in fusion (6). This is due to the lack of specificity by 
NEM, as it only requires free thiol groups to function. Even though the dosage of NEM required 
to inhibit Sec18/NSF is in the millimolar range (5, 7), its promiscuity may have even been 
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advantageous (8) to its use in adopting early models identifying the interaction of Sec18/NSF with 
Sec17/a-SNAP as being crucial to the continual cycle of fusion by membranes within the cell  
(9).    
  
We previously demonstrated the importance of phosphatidic acid (PA) in regulating Sec18/NSF 
priming activity (10–12). Deletion of the PA phosphatase PAH1, the yeast orthologue of 
mammalian lipin1, leads to elevated concentrations of PA on the vacuole that we hypothesized 
sequesters Sec18 away from cis-SNAREs (10). Even when Pah1 is present, released Sec18 can be 
inhibited by adding soluble dioctanoyl PA (C8-PA). Conversely, deleting the diacylglycerol 
(DAG) kinase DGK1 elevates vacuolar DAG levels at the cost of lowering PA concentrations 
while resulting in augmented fusion (13). Thus, the temporal regulation of balancing PA and DAG 
concentrations has a direct effect on progression through the fusion pathway. Subsequent studies 
showed that PA binding by monomeric Sec18/NSF triggers large conformational changes that 
appear to be incompatible with the assembly of the active homohexamer needed to bind and prime 
SNAREs (12). The major site of conformational change, as shown by molecular dynamics, is the 
predominant PA binding site between the D1 and D2 domains of NSF.   
  
Although PA serves as a natural regulator of Sec18 function, it has multiple limitations as a tool 
to further probe the mechanics of priming. The principal limitation with relying on PA as an 
inhibitor of Sec18 activity is due its insolubility, as it is part of the membrane bilayer, as well as 
its susceptibility to dephosphorylation by Pah1. Additionally, PA binds other proteins including 
the vacuolar SNARE Vam7 (14). Finally, PA is likely to serve both as an inhibitor of Sec18 activity 
while being a positive regulator through its interactions with Vam7. In fact, reconstituted 
proteoliposome fusion systems show that PA is essential for fusion to occur when the priming 
stage is eliminated (15).   
  
Taken together, the lack of NEM specificity and the duality of PA in regulating vacuole fusion 
was the impetus for finding a specific soluble small molecule inhibitor of NSF/Sec18 function. 
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We used structural data of NSF (16) to computationally screen for compounds that bound to the 
previously mapped PA binding site. Through this we discovered an uncharacterized molecule that 
we call IPA (Inhibitor of Priming Activity). IPA bound to Sec18 with high affinity and potently 
blocked SNARE priming and downstream vacuole fusion. Biochemical, biophysical and 
molecular dynamics examination of IPA-Sec18 complexes led us to conclude that IPA “locks” 
NSF/Sec18 into a rigid conformation that it incompatible with SNARE priming presumably by its 
ability to inhibit NSF/Sec18 binding to PA as shown below.   
 
RESULTS 
Identification of a small molecule inhibitor of Sec18 binding to PA – Because PA acts a potent 
inhibitor of Sec18 function we used computational modeling to search for small molecules that 
docked at the previously identified PA binding regions of Sec18 (12). To accomplish this, we used 
the cryo-EM guided resolution of the hexameric structure of NSF bound to SNAREs (17). 
Schrodinger’ SiteMap (18) was then performed on both hexameric and monomeric forms of NSF 
as well as a homology models of Sec18 hexameric and monomeric forms generated using 
Schrodinger Prime (19, 20). The top resulting binding sites for both NSF/Sec18 hexamer and 
monomer were docked using all compounds available from the Illinois High Throughput Facility 
initially using Glide HTVS, and the top hits were docked using Glide XP (19). Our screen included 
compounds from the Illinois high throughput screening facility (HTSF), NCI Open, NCI Diversity, 
and the Chembridge microformat libraries, which were prepared for docking using LigPrep 
(Schrödinger Release 2018-2: LigPrep, Schrödinger, LLC, New York, NY, 2018). Of the boxes 
examined, the 3rd and 4th highest lowest average gscore for binding to PA. Compounds with the 
best gscore, or lowest predicted DG for box 3 and 4 using Glide HTVS, were selected to be further 
docked using the more computationally intensive Schrödinger XP (21). Of these compounds, 19 
were selected from the NCI Diversity set according to gscore with corresponding SiteMap sites. 
In Figure 3.1B we show the structures of the top 12 candidates for Sec18 binding including 
epirubicin and 7-Methyl-3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9yl)bicyclo[2.2.1]hept-5-ene-2-
carboxylic acid, the compound we have now named inhibitor of priming activity (IPA) (Fig. 3.1B). 
In Figure 3.2A-D we show epirubicin and IPA binding to box 3 and 4 with key interactions 
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depicted by lines between Sec18 residues and the small molecules. From these docking 
experiments we found that IPA and epirubicin had the highest gscores of the candidate compounds 
(Fig. 3.2E). The interactions between the D1-D2 domains of NSF with both epirubicin and IPA 
structures were further examined by using a computational ensemble docking methodology in 
order to verify the poses chosen for screening (Fig. 3.2F-G). Both epirubicin and IPA showed 
clustering at the hinge region between the D1 and D2 domains, and a second distal location in the 
D2 domain. Epirubicin showed additional binding to a second region at the D1-D2 hinge.   
  
The group of candidate compounds, including epirubicin and IPA were further screened for their 
ability to inhibit vacuole fusion inhibition at 100 µM. Compounds that inhibited fusion by >50% 
were next screened for the inhibition of priming. From the starting pool of chemicals, significant 
priming inhibition was only observed with epirubicin and IPA, which were further rigorously 
tested (See below in Fig. 3.6). Epirubicin was later ruled out as a potential candidate for 
characterizing the mechanism for PA regulation of priming when it showed no competition for 
Sec18 to PA liposomes (data not shown), and exhibited a greater than predicted KD approaching 
millimolar concentrations for binding monomeric Sec18 (Fig. 3.6I). We attributed the ability of 
epirubicin to alter vacuole fusion to its integration into the membrane, as similar molecules interact 
with the phospholipid bilayer by insertion (22, 23).  
  
Sec18 monomer, D1, and D2 Domains bind IPA with high affinity – To further determine whether 
IPA could serve as a specific inhibitor of Sec18, we next measured its dissociation constant. To 
this aim we used Label-free microscale thermophoresis (LFMST), labeled MST (MST), and 
surface plasmon resonance (SPR). All three techniques yielded a KD in the low µM range for IPA 
binding to monomeric Sec18 (mSec18). Labeled MST showed that mSec18 bound to IPA with a 
KD of 3.84 ± 1.3 µM (Fig. 3.3A and Table 3.1). Similarly, LF-MST showed that mSec18, labeled 
with Ni-NTA Atto 488, bound to IPA with a KD of 7.4 ± 3.7 µM (Fig. 3B). Discrepancies between 
the KD values of mSec18 to IPA using MST can be explained by the presence of the Atto 488 dye 
in the labeled experiment or as a result of IPA having measurable light absorbance (data not 
shown). We further verified these affinity measurements using surface plasmon resonance (SPR) 
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where mSec18-His8 was linked to an Ni-NTA Biacore chip, after which IPA was flowed and 
response units (RU) were measured. SPR measurements yielded a KD of 4.08 ± 0.83 µM (Fig. 3C), 
which was consistent with the MST results. Together these results indicated that IPA bound Sec18 
with high affinity.   
  
Next, we determined which Sec18 domain contributed most to binding IPA. Using SPR, we tested 
the individual D1 and D2 domains, as well as a D1-D2 continuous polypeptide. These were added 
to separate channels of a Ni-NTA chip with fresh protein loaded between each injection. Capture 
of proteins per kinetic injection on the chip ranged from 20502900 RU for D1, 1500-2500 RU for 
D2, and 14001600 RU for D1-D2. The KD of IPA for D1 was determined from the sensorgrams as 
320 nM (Fig. 3.3D). The KD of IPA for D2 was 1.1 µM (Fig. 3.3E), while the KD for D1-D2 was 
958 nM (Fig 3.3F). We reasoned that the improved affinity for the domains was either the result 
of having measured the affinity via kinetic measurements as opposed to steady state measurements 
used above (Fig. 3.3A-C). Importantly, the on-rate for the D1-D2 construct was over 4-fold greater 
than for either D1 or D2 alone indicating that there may be some cooperativity between the D1 
and D2 domains upon the initial recognition of PA. Together this data shows that both Sec18 
domains participate in binding IPA similar to PA shown previously (12).   
  
IPA inhibits Sec18 binding to PA Liposomes – In order to test whether IPA inhibits Sec18 binding 
to PA, we titrated IPA in the presence of PA liposomes and mSec18. Liposomes for floatation 
experiments (Fig. 3.4A-B) were prepared as previously described (12). IPA was added at the 
concentrations indicated in the presence of mSec18 at a final concentration of 500 nM. This 
showed that IPA blocked mSec18 binding to PA liposomes with an IC50 of 3.2 µM, which was 
near the KD values IPA binding to mSec18 in Figure 3 (Fig. 3.4A and Table 3.2). This data was 
consistent with previous SPR competition experiments using PA containing nanodiscs (24). To 
examine if IPA blocked other PA binding proteins we used the DEP domain from the murine 
protein Dvl2 (25). Previously we used DEP to bind PA liposomes and vacuolar PA to displace 
Sec18 from membranes (11). Here we tested PA liposome binding DEP in the presence of 100 µM 
IPA. Unlike the competition we observed with Sec18, IPA was unable to compete at greater than 
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50% inhibition with DEP for PA binding at this IPA concentration (Fig. 3.4B). This suggested that 
IPA was specific for the Sec18-PA binding interface. We also tested IPA against the soluble 
SNARE Vam7, which binds PI3P and PA (14). To ensure that the PI3P binding domain was not 
contributing to PA binding we used the Y42A mutation in the PI3P binding site of the Vam7 PX 
domain (26). This experiment was performed by SPR where 800 nm extruded PA liposomes (close 
to the size of the yeast vacuole) were bound to an L1 Biacore chip, after which Vam7Y42A was 
injected and bound to saturation (Fig. 3.4C). When IPA was used at 100 nM, we observed no 
difference in Vam7Y42A binding to the PA liposomes. In comparison, IPA competed with Sec18 
binding to the immobilized PA liposomes considerably at 100 nM (Fig. 3.4D).   
  
In order to test whether IPA action was specific to anionic phospholipids we further checked 
whether it affected binding of mSec18 and Vam7Y42A to phosphatidylinositol (PI) containing 
liposomes.  Both mSec18 and Vam7Y42A showed low overall binding to PI liposomes (Fig. 3.4D).  
Additionally, the inhibitory effect of IPA was absent when either Vam7Y42A or Sec18 were bound 
to PI liposomes.  Together these data further verify the specificity of IPA for mSec18 to PA.    
   
We then asked whether D1 or D2 domains of Sec18 were more or less important to IPA 
competition of PA as both domains were previously shown to bind PA (12). First, we measured 
the binding of each domain to immobilized 100 nm extruded PA liposomes. In Figure 3.4E, we 
show full length monomeric Sec18 and the D1 and D2 domains bound with similar affinities to 
the immobilized PA liposomes. Specifically, the KD was 781 ± 110 nM for D1, 866 ± 669 nM for 
D2, 505 ± 267 nM for mSec18. Next, IC50 values for IPA and PA binding were determined using 
concentrations of mSec18, D1 and D2 near or above the KD values derived from liposome binding 
using constant concentration of 250 nM mSec18, 1000 nM D1, and 1000 nM D2 (Fig. 3.4F).    
  
IPA inhibition of Sec18 binding to PA liposomes is not affected by membrane curvature – Next, 
we tested whether membrane curvature affected mSec18 binding and the effects of IPA. To this 
aim we used 3 different extrusion filters of 100, 400, and 800 nm containing 5% PA. The different 
sized liposomes bound to an L1 chip in HBS-N buffer for SPR analysis. First saturation was 
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determined for each liposome type, which showed that mSec18 bound 800 nm liposomes with a 
KD of ~ 670 nM compared KD values of ~1600 nM and ~1000 nM to the 100 and 400 nm diameter 
liposomes (Fig. 3.5A). Although this showed that mSec18 bound more strongly to 800 nm 
liposomes, the binding affinities to smaller vesicles were still high. To determine whether 
membrane curvature affected how IPA blocked mSec18 from binding liposomes, we tested the 
competition of 100 nM IPA with 250 nM mSec18 for liposome binding. Reactions were incubated 
as before and liposomes were re-isolated by flotation. This showed that IPA reduced Sec18 (0.5 
µM) binding by 90% to 800 nm liposomes, whereas IPA inhibited binding by 80 and 70% to 400 
nm and 100 nm liposomes, respectively (Fig. 3.5B). While these results show differences in 
binding in the presence or absence of IPA, the fact remains, that IPA potently inhibits Sec18 from 
interacting with PA liposomes.   
  
To determine whether IPA competition for Sec18 damages liposomes, we examined membrane 
integrity by using a Calcein dequenching assay. Here we used extruded 100 nm liposomes in the 
presence of 100 mM Calcein to capture the fluorophore at selfquenching concentrations (27, 28). 
Calcein loaded liposomes were treated with buffer, 0.2% Triton X100 or a dosage curve of IPA. 
As controls, we found that incubating with buffer had no effect on Calcein fluorescence, while 
Triton treatment led to increased fluorescence, indicating that the dye became diluted and de-
quenched when the liposome was dissolved (Fig. 3.5C-D). When Calcein liposomes were 
incubated with IPA, there was no observable increase in fluorescence, demonstrating that IPA had 
no effect on the integrity of the liposomes.   
  
While IPA did not damage liposome integrity, we next asked if this compound altered liposome 
diameter or dispersal. To address this, we used dynamic light scattering (DLS) to compare 80/20 
PC/PE liposomes to 75/20/5 PC/PE/PA 100 nm extruded liposomes and found that there was no 
appreciable difference in size as between the two liposome types (data not shown). To test if IPA 
affected the recovery of liposomes after flotation, we used DLS and measured the peak intensities 
(kilocounts per second) of 100 nm extruded liposomes listed above. In the absence of IPA, ~ 80% 
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of the starting material was recovered, while ~90% was recovered in the presence of 100 µM IPA 
(Fig. S2B). Taken together, IPA had no effect on liposome size or flotation.   
  
IPA Inhibits Fusion and Priming – The primary goal of finding a small molecule that specifically 
binds Sec18 was to use it to block SNARE priming and halt the fusion pathway. To test this, we 
used a vacuole fusion tester set where half of the vacuoles in a fusion reaction harbored inactive 
pro-Pho8 (alkaline phosphatase) and lacked the protease Pep4. The second set contained Pep4 but 
lacked proPho8. Upon membrane fusion and content mixing Pep4 gained access to pro-Pho8 and 
cleaved the inhibitory pro-peptide to yield active Pho8 that can be tested as proxy for vacuole 
fusion efficiency. In Figure 3.6A, we show that IPA blocked fusion as measured by Pho8 activity 
with an IC50 of ~50 µM. The concentration needed to block fusion was notably higher that the 
dose needed to inhibit binding to PA liposomes. We attribute this to the accessibility of Sec18 
interacting with the fusion machinery, and potentially the predominance of hexamer over monomer 
in this assay. Nevertheless, this is the first demonstration of a specific Sec18 ligand to inhibit 
membrane fusion. In comparison, inhibiting fusion with NEM requires millimolar concentrations 
(11).   
  
To verify if IPA inhibited fusion during the priming stage, we performed multiple tests. First, we 
tested IPA in a gain of resistance assay. Here, individual fusion reactions were treated with buffer 
as a control, IPA, or antibody against Sec17 to directly block the priming machinery. The reagents 
were added at different time points to ask if fusion was still sensitive to the inhibitor. Thus, as a 
stage of fusion (e.g. priming) is passed, reagents that target the stage loses their efficacy. In Figure 
3.6B we found that fusion reactions gained resistance to IPA with similar kinetics to those of anti-
Sec17 antibody. In other words, as the bulk of fusion reactions passed the priming stage, both IPA 
and anti-Sec17 lost their ability to inhibit fusion. The similarity in the rate in which these reagents 
lost their inhibitory effect indicated that IPA only inhibited fusion at the priming stage. In parallel, 
untreated reactions were placed on ice to stop maximal fusion at each time point indicated, to 




To test the effect of IPA directly on SNARE priming we used the release of Sec17 as a measure 
of Sec18 function (3, 11). As Sec18 disassembles cisSNARE complexes, the co-chaperone Sec17 
is released from the membrane and accumulates in the supernatant after membranes are pelleted 
by centrifugation. We tested IPA in comparison to NEM and C8-PA and found that IPA blocked 
Sec17 release as strongly as NEM and C8-PA (Fig. 3.6C-D). Both NEM and C8-PA inhibited 
priming as previously reported (11). However, both NEM and C8PA lack specificity for Sec18, 
thus IPA is the first specific inhibitor of SNARE priming. Finally, we determined if the inhibitory 
concentration IPA was similar for both overall fusion inhibition and SNARE priming. A range of 
IPA concentrations was added to vacuoles and incubated for 30 min after which membrane were 
pelleted and the supernatants collected for Western blotting. Sec17 release was blocked by IPA 
with an IC50 of ~50 µM (Fig. 3.6E-F), which matches the IC50 for content mixing. To determine 
whether the effect of IPA was reversible, we added exogenous recombinant hexameric Sec18 to 
fusion reactions first incubated with IPA. In Figure 3.6G we show that IPA inhibited fusion as 
seen above. When 5.3 µM Sec18 was added, we found that vacuole fusion was restored. Adding 
Sec18 alone had no effect on vacuole fusion.  
  
We next verified whether the effect of IPA on priming was not due to membrane damage. To this 
aim we incubated vacuoles in fusion reaction buffer alone or in the presence of 0.2% Triton X-
100, 100 µM IPA or 100 µM Epirubicin. After incubating for 30 min at 27ºC, the reactions were 
fractionated by centrifugation to separate membranes from solubilized material. To monitor the 
release of luminal content, we probed for the soluble luminal protease Pep4 by Western blotting. 
Pep4 remained in the membrane fraction when vacuoles were treated with IPA, Epirubicin or 
buffer alone (Fig. 3.6H). As a control we used Triton X-100 to solubilize the vacuoles and release 
Pep4 into the supernatant. We also probed for the distribution of the Rab GTPase Ypt7 as a marker 
for membrane proteins. Similar to what we saw with Pep4, Ypt7 remained in the membrane 
fractions unless the vacuoles were treated with Triton X-100. Together this further demonstrates 




To compare the effects IPA with another small molecule candidate we tested Epirubicin. While 
Epirubicin was predicted to bind Sec18, we found that it bound poorly with a KD of 677 ± 179 µM 
(Fig. 3.6I). We further tested Epirubicin by using a dosage curve in fusion reactions. We found 
that it reduced fusion, albeit with an IC50 > 400 µM (Fig. 3.6J). Due to the poor binding to Sec18, 
we attributed the inhibition of fusion by Epirubicin to its ability to insert into membranes. This 
was evident by the bright pink coloring of liposomes or vacuoles when incubated with Epirubicin 
(not shown). Together, these data illustrate that even though Epirubicin was initially predicted to 
bind Sec18 at similar sites as IPA, it was ineffective in altering Sec18 function, thus bolstering the 
significance of discovering IPA.   
  
IPA does not induce conformational changes in Sec18 – In order to determine how IPA operates, 
we asked if it could alter Sec18 conformation in a manner similar to what we previously observed 
with PA (12). In that work we showed that PA induced conformational changes in full length 
Sec18 allowing for increased proteolytic cleavage, whereas DAG and phosphatidylserine had no 
effect. Here we compared the conformational changes induced by PA binding Sec18 with any 
affects that IPA might have. We incubated Sec18 with a titration curve of Thrombin in the absence 
or presence of 100 µM IPA. As shown in Figure 3.7A IPA did not result in increased Thrombin 
cleavage. Instead, IPA protected Sec18 from cleavage relative to the buffer control. This is the 
opposite to the effect of PA binding to Sec18, which results in enhance cleavage. As a control, we 
incubated with Sec18 with Thrombin and PA as previously described. As predicted Thrombin 
cleaved Sec18 more efficiently when C8-PA was present (Fig. 3.7B). While IPA reduced Sec18 
cleavage, the same major degradation products were found with buffer, IPA or PA. The cut sites 
for generating these products were determined by mass spectrometry. Thrombin cleaved Sec18 at 
R225 to give a C-terminal 60 kDa fragment (p1). K378 to give the C-terminal 30 kDa fragment 
(p2). The 25 kDa fragment was generated by cleaving at R225 and K455 (p3).   
  
To further test the effects of IPA on Sec18 we next examined proteolytic cleavage of subdomains. 
In Figure 3.7C-D we show the effects of IPA and PA on Thrombin cleavage of N-D1. In reaction 
buffer alone Thrombin cleavage produced a 31 kDa by cutting at K100 and R360 (p1). The 25 
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kDa band was a product of cutting at R225 and K455 (p2). As seen with full length Sec18, we 
found that IPA reduced the magnitude of cleavage (Fig. 3.7C). This suggests that IPA either blocks 
Thrombin sites or induces a distinct conformational change that masks cleavage sites. 
Interestingly, incubating with C8-PA had no effect on the level of proteolysis compared to the 
buffer control (Fig. 3.7D). This suggests that the absence of the D2 domain is needed for PA 
induced conformational changes that expose Thrombin sites. This does not exclude the possibility 
conformational changes that do not expose cleavage sites.   
  
Next, we tested the D1-D2 continuous domains and found that thrombin cut at R423 to produce a 
C-terminal fragment (p1). A second cleavage occurred at K547 to yield a 23 kDa product. Here 
we found that IPA mildly reduced cleavage at the lowest Thrombin concentrations (Fig. 3.7E). 
This suggests that the N-domain is required for the protective effects of IPA. In comparison, D1-
D2 remained sensitive to PA binding as shown by the increased cleavage shown in Figure 3.8. 
The inability of PA to induce more cleavage in D1-D2 suggests that its effect requires the N-
domain as part of the entire protein to induce the full conformational change.  
  
IPA binding blocks the effect of PA on thrombin cleavage – Because of the overlap in predicted 
binding sites for IPA and PA, we tested whether binding IPA first would block the effects of PA 
on Sec18 cleavage by thrombin. We indeed found that 100 µM IPA protected Sec18 from cleavage 
(Fig. 8). We interpret this as one of two possibilities. One is that IPA directly blocked PA binding. 
The second is that IPA induces a conformational change distinct from the one induced by PA in 
which key PA binding sites were obscured. Because IPA alone had no effect on Sec18 cleavage, 
it is more likely that the former scenario occurs.   
  
To corroborate the limited proteolysis data, we performed ANS fluorescence assays. When ANS 
binds to exposed hydrophobic areas, it undergoes fluorescence dequenching, thus changes in ANS 
fluorescence between different conditions can serve as a reporter for conformational changes. (12). 
Previously we used ANS fluorescence to show that full length Sec18 underwent conformational 
changes when bound to PA, but not DAG or PS. The effects of PA binding on Sec18 were further 
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examined using MD simulations on the D1-D2 domains. The Ndomain was excluded due to its 
promiscuous binding to anionic surfaces. Nevertheless, it remained possible that PA binding would 
induce changes between the N and D1 domains. This is of particular importance as studies by 
others have shown that the N-domain undergoes conformational changes with respect to the D1-
D2 domains when hexameric Sec18 catalyzes SNARE priming at the expenditure of ATP  (16, 
29–31).  
  
Here we used ANS fluorescence assays to test whether the conformational changes were indeed 
limited to the D1 and D2 domains, or whether additional changes occurred between the N and D1 
domains. First, we tested N-D1 by incubating it with a dose curve of C8-PA. We observed an 
increase in fluorescence as C8-PA concentrations increased, suggesting that there was some level 
of conformational change, however, the difference versus the control without PA was not 
statistically significant (Fig. 3.9A, E). We next tested the effect of C8- PI(4,5)P2 on N-D1 and 
found very little change compared to the control (Fig. 3.9B).   
  
We continued with the D1-D2 construct and PA. Previously we mapped PA binding sites to the 
hinge region between D1 and D2, so we expected to see an increase in ANS fluorescence with the 
shortened protein when bound to PA (12). The showed a large statistically significant increase in 
ANS fluorescence when incubated with C8-PA (Fig. 3.9C, E). In contrast, incubating D1-D2 with 
C8- PI(4,5)P2 had no effect on ANS fluorescence (Fig. 3.9D).  
  
The lack of a significant change in ANS fluorescence with N-D1 is consistent with the Thrombin 
cleavage patterns seen above. In both cases, the presence of PA had no apparent effect on 
conformational changes. The lack of ANS fluorescence changes in the presence of PI(4,5)P2 
suggests that this lipid interacted poorly with the Sec18 constructs. This is in keeping with our 
previous report where we measured the KD for Sec18 to PI(4,5)P2 as >400 µM (12). Together, 
these results indicated that the conformational changes seen in Sec18 upon PA binding primarily 




IPA Binding and Molecular Dynamics Ensemble Docking – To further probe the interactions of 
Sec18 with PA and IPA, we performed ensemble molecular docking. We next analyzed scores of 
the poses from each cluster and selected poses for epirubicin, IPA, and PA from the interquartile 
region and the highest overall pose corresponding to the lowest DG representation for D1-D2 to 
run MD simulations for 100 ns. These results were further analyzed by determining the water 
exposure around the predicted thrombin cut residue for mSec18 of R638 using R628 on NSF (Fig. 
3.10A). We then compared the average RMSD across the entire simulation trajectory for NSF D1-
D2 using C8-PA (Fig. 3.10B), IPA (Fig. 3.10C), and epirubicin (Fig.  
3.10D) over the course of the 100 ns simulations.  
  
In these simulations it appears that IPA hindered initial conformational change in D1-D2 relative 
to PA, as there is a significant difference in overall RMSD starting at about 20 ns of the MD 
simulations, where PA has roughly a 15 Å average RMSD versus ~ 6 Å average RMSD for the 
IPA simulation (Fig. 3.10B-C). This conformational difference was explored by determining water 
accessibility as shown in Figure 3.10A, which could limit access for proteases explaining the 
results in Figure 3.10A-B. We postulate that IPA inhibits mSec18 binding PA by preventing the 
conformational change necessary for binding the lipid. Additionally, simulations on epirubicin 
demonstrate an average RMSD of approximately 5 Å, over the entire 100 ns simulations (Fig. 
3.10D). The fact that IPA and epirubicin appear to lock the conformation of Sec18, whereas PA 
appears to stimulate conformational change leads to the conclusion that they have different modes 
of binding, even though IPA appears to competitively inhibit Sec18 binding to PA in biochemical 
assays.    
DISCUSSION 
 
Membrane fusion is required for vesicular trafficking and eukaryotic homeostasis. While most 
trafficking pathways have a unique signature of organelle-specific SNARE proteins, every set of 
SNAREs relies on Sec18/NSF, which is the only protein responsible for catalyzing the disassembly 
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of SNARE complexes at the expense of ATP (32). Thus, it is important to develop tools to enable 
further study of this mechanism because of its ubiquitous operation on almost all organelle types. 
In this study we used structure based computational drug discovery to find a specific inhibitor of 
Sec18/NSF function that we call the Inhibitor of Priming Activity, or IPA. Although the structure 
of NSF was used to computationally dock chemical libraries, the candidate compounds were 
expected to bind Sec18, as these orthologs have been shown to be interchangeable (7, 33, 34).  
  
Previous to the discovery of IPA, there was a complete lack of specific small molecule inhibitors 
to block SNARE priming. In fact, the only way to specifically inhibit NSF activity was to raise an 
antibody against it. As its name indicates, NSF (NEM sensitive factor) was discovered by it 
sensitivity to the alkylating agent N-Ethylmaleimide (NEM), which promiscuously modifies free 
thiols (35). Although NEM does inhibit SNARE priming in our system, it has downstream effects 
which are likely due to promiscuous alkylation, for example, NEM could additionally alkylate 
other proteins involved in SNARE function such as the single Cys on the SNARE Vam7 (11).   
  
In this study we report that IPA inhibits SNARE priming and subsequent vacuole fusion. 
Previously we found that priming could be inhibited by the PA phosphatase inhibitor propranolol 
(10). Although non-specific, the results from using propranolol led us to determine that Sec18 
bound to PA reservoirs on the vacuole membrane that sequestered Sec18 away from cis-SNARE 
complexes (11). It is only after the PA phosphatase Pah1 converts enough PA to DAG that Sec18 
is able to dissociate from the membrane and engage the SNARE complex. Through this we also 
found that C8-PA could be added to in vitro reactions and potently block priming by preventing 
Sec18 from attaching to SNAREs. The ability of C8-PA to inhibit SNARE priming was not 
entirely specific to priming, as it also inhibited downstream stages of the fusion pathway as 
indicated by gain of resistance assays. We attribute the later effects of C8-PA to interacting with 
the SNARE Vam7, which binds both PI3P and PA (14). While both propranolol and C8-PA helped 
to further understand Sec18 regulation, a more specific molecule such as IPA was in order to 
determine with more specificity the effect of PA on Sec18 priming, and not additional stages of 
fusion. Unlike propranolol and C8-PA, IPA does not appear to have downstream effects on the 
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fusion machinery. This is due to the specificity of IPA for NSF/Sec18 at the PA-binding interface 
while the aforementioned propranolol and C8-PA do not specifically bind a single protein. 
Importantly, the lack of an effect after priming indicates that IPA does not inhibit the newly 
discovered priming-independent role of Sec18 in SNARE zippering at the docking stage (36).  
  
Using molecular docking and MD simulations, we found that IPA bound to NSF at the hinge 
region of D1 linking to the D2 domain. This region of NSF overlaps with regions bound by the 
lipid PA (12). Consequently, IPA could compete for PA binding by Sec18 on liposomes. This was 
a specific competition as IPA failed to compete for PA binding against DEP and Vam7Y42A, or 
significantly interfere with interactions between Sec18 and PI liposomes.  With regards to the two 
binding sites, IPA showed the best competition at the D1 hinge site, which coincides with the key 
regulatory site of PA binding, and the fact that PA bound D1 better than any other domain of Sec18 
alone (10). When PA binds NSF it induces a conformational change at the hinge region causing 
the two domains to swing towards and away from each other, creating both closed and open forms 
of NSF. The “closed” conformation of NSF is incompatible with hexamerization and SNARE 
priming activity. We now show that IPA binds in the same hinge region and prevents its change 
to the closed conformation, presumably inhibiting the conformational change necessary for Sec18 
to bind PA and potentially explaining the inhibition of Sec18 binding to soluble SNAREs shown 
previously (10). Instead, IPA appears to make the Sec18 protomers more rigid, which may in turn 
prevent interactions with Sec17 and cis-SNARE complexes.  
  
In summary, we now report the discovery of a novel small molecule that inhibits SNARE priming 
through binding Sec18/NSF. Due to the lack of any such inhibitor, IPA will serve as a potent tool 
to examine the nature of Sec18/NSF function and SNARE priming. While IPA was potent in the 
inhibition of Sec18, we expect that it will have a lower KD and better activity towards NSF, as the 
molecule was found using the NSF structure. Thus far, only in vitro systems have been thoroughly 
tested with IPA, but preliminary in vivo tests with mammalian cells indicate that IPA is membrane 
permeable and active at nanomolar concentrations (Sparks & Fratti, unpublished). This suggests 






Reagents – All reagents were diluted in PS buffer (20 mM 1,4-piperazinediethane sulfonic acid 
(PIPES)-KOH pH 6.8 and 200 mM sorbitol) to a working concentration before use in an 
experiment. Antibody to Sec17 was described previously (37). POPA (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphate), POPC (1-palmitoyl-2-oleoyl-sn-glycero-3phosphatidylcholine), POPE (1-
palmitoyl-2oleoyl-sn-glycero-3-phosphatidylethanolamine), C8-PA (1,2-dioctanoyl-sn-glycero-
3-phosphate) were purchased from Avanti Polar Lipids as chloroform stock solutions and stored 
at -20°C. CM7, CM5, Ni-NTA (Standard and S series) and L1 sensor chips, and Regeneration 
buffers (Glycine pH 13) were procured from GE Healthcare. Ni-NTA Atto 488 dye, N-
Ethylmaleimide (NEM) and Calcein were procured from MilliporeSigma. Monolith NT.115 
standard treated capillaries for thermophoresis were purchased from Nanotemper (München 
Germany). Epirubicin was from Cayman Chemical. 7-Methyl-3-(4,5,6-trihydroxy-3-oxo3H-
xanthen-9-yl)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid was procured via Ambinter under the 
identification numbers Amb16226271 and Amb4002159.   
  
IPA purity was assessed using NMR and LC/MS. NMR data was recorded on a Bruker 
spectrophotometer equipped with a CryoProbe (500 MHz, 1H) using deuterated dimethyl 
sulfoxide as a solvent and internal reference (δ = 2.50 ppm). LC/MS data was performed by the 
University of Illinois Mass Spectrometry Laboratory using a 2.1 mm ID reverse phase C-18 
column and a Waters Synapt G2Si mass spectrometer (ESI).  
Recombinant proteins – Recombinant expression of C-terminally His8 tagged full length Sec18, 
or its domains (N, D1, D2, D1-D1) were purified from Escherichia coli as previously described 
(12). Briefly, pSec18His8 (or one for a domain derivative) was transformed into Rosetta 2 (DE3) 
pLysS Competent Cells (Novagen) and Sec18-His8 expression was carried out using auto-
inducing medium (AIM) (38). Cells were grown to stationary phase (37°C, 18 h, shaking) and 
harvested by centrifugation. Cells were resuspended in lysis buffer (20 mM HEPES pH 6.8, 300 
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mM NaCl, 0.1% Triton-100, 2 mM 2-mercaptoethanol, 20 mM imidazole, 10% glycerol, 1 mM 
ATP, 1 mM PMSF, and 1X cOmplete Protease Inhibitor Cocktail (Roche)) and lysed by French 
press. Lysates were clarified by centrifugation (50,000 x g, 20 min, 4°C) and incubated with Ni-
NTA resin (Invitrogen) overnight at 4°C. Next, resin was washed with (100 bed volumes of lysis 
buffer with 50 mM imidazole) after which protein was eluted in 1 ml fractions (lysis buffer with 
250 mM imidazole). Protein was concentrated by centrifugation using a 100 kDa cutoff Centricon 
before resolving by gel filtration (Superose 6) using size exclusion buffer (20 mM HEPES pH 6.8, 
300 mM NaCl, 1 mM 2-mercaptoethanol, 10% glycerol). Sec18-His8 elutes in two peaks 
corresponding to monomeric and hexameric pools (Fig. S1). Each pool was collected and 
concentrated before use. The DEP PA binding domain from murine Dvl2 was purified as a GST-
fusion as described (25). Membrane scaffold protein 1D1 (MSP1D1-His) was prepared as 
described (39). GSTVam7Y42A was expressed and purified as described (40).   
 
Calcein dequenching and membrane integrity – Liposomes were extruded in the presence of 100 
mM Calcein to encapsulate the dye at self-quenching concentrations (27, 28). Liposomes were 
dialyzed in 4L of TBS pH 7.4 (10 mM Tris-Cl pH 7.5, 140 mM NaCl, 10 mM EDTA pH 8.0, 0.5% 
SDS) to remove excess un-encapsulated dye. Encapsulated Calcein liposomes were incubated with 
buffer, 0.2% Triton X-100, or a dose curve of IPA. Upon lysis, Calcein becomes diluted and 
fluorescence increases (ex. 494 nm, em. 515 nm).  
  
Vacuole Isolation and in vitro vacuole fusion assay – Vacuoles were isolated from yeast strains by 
density gradient floatation as previously described (41). Fusion reactions (30 µL) contained 3 µg 
each of vacuoles from BJ3505 (pep4∆ PHO8) and DK6281 (PEP4 pho8∆), fusion assay buffer 
(125 mM KCl, 5 mM MgCl2, 20 mM PIPES-KOH pH  
6.8, 200 mM sorbitol), ATP regenerating system (1 mM ATP, 29 mM creatine phosphate, 0.1 
mg/ml creatine kinase), 10 µM CoA, and 283 nM Pbi2p. Reactions were incubated at 27°C for 90 
min and the Pho8 activity was measured in 250 mM Tris-Cl PH 8.5, 0.4% Triton X-100, 10 mM 
MgCl2, 1 mM p-nitrophenyl phosphate. Fusion-dependent alkaline phosphatase maturation was 
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measured by the amount of p-nitrophenylate produced. p-Nitrophenylate absorbance was 
measured at 400 nm.  
  
Liposome Preparation and Co-Floatation Assay  - Large unilamellar liposomes were prepared 
using an extrusion method (42). Extruded liposomes were prepared with 1 mM concentration of 
appropriate lipids 75% PC, 20% PE, and 5% PA, which were heated and passed through an Avanti 
mini-extruder equipped with filters of sizes 0.1, 0.4 and 0.8 µm filters over 10 times to assure 
homogeneous liposome sizes. Small unilamellar liposomes containing various lipid compositions 
were prepared using the sonication method (15). Briefly, stock lipids in chloroform were mixed to 
produce a lipid mixture with the desired lipid mole percentages of 2.6 µmoles of total 
phospholipids. The lipid mixture was dried under a gentle stream of nitrogen and dried in a speed-
vacuum for an additional 60 min. The tubes were placed under vacuum in a desiccator for an 
additional 14 h. To the dried lipids, 2.6 mL of 1X PBS solution was added. Tubes were covered 
with parafilm and incubated at room temperature for 1 h. The lipids were resuspended with 
vortexing and disrupted in a water bath sonicator for 30 min.   
  
To measure protein binding to liposomes we used a floatation assay as described (43). Briefly, 40 
µL of lipid binding domain/PBS mixture was incubated with 150 µL of the 1 mM liposome 
suspension for 5 min at 30°C before 20 µg of recombinant Sec18His8 was added to bring up the 
total volume to 200 µL and give a final concentration of 1.2 µM Sec18. Samples were incubated 
for an additional 10 min at 30°C and 630 µL of 1.65 M sucrose (PBS) was added. Samples were 
loaded into the bottom of a centrifuge tube and layered with 840 µL of 0.75 M sucrose (PBS), and 
1X PBS to the top of the tube. Samples were centrifuged (200,000 x g, 90 min, 4°C) and 200 µL 
of floated liposomes were recovered from the top of the 0.75 M sucrose layer. The bottom 100 µL 
fraction was recovered and SDS sample buffer was added to sample unbound protein levels. 
Liposomes were resuspended in 1 mL of 1X PBS and isolated by centrifugation (16,000 x g, 10 
min, 4°C). SDS sample buffer was added to the final liposome pellet and bound proteins were 
resolved by SDS-PAGE. The proteins were transferred to nitrocellulose and probed by Western 
blotting. Images were acquired using a ChemiDoc MP Imaging System (Bio-Rad).  Additionally, 
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protein binding and inhibition of protein binding via inclusion of IPA to extruded liposomes was 
measured using SPR.   
  
Priming Assay – Priming activity of Sec18 was assayed as previously described (11). Briefly, 
vacuoles were harvested from BJ3505. The equivalent of two standard fusion reactions was 
incubated at 27°C with buffer, 1 mM NEM, 300 µM C8-PA, or 100 µM IPA. At the indicated 
times, vacuoles were removed by centrifugation (16,000 x g, 5 min, 4°C) and SDS sample buffer 
was added to the supernatants. Samples were heated at 95°C for 5 min, resolved by SDS-PAGE, 
transferred to nitrocellulose, and probed by Western blot.   
  
Surface Plasmon Resonance – Surface plasmon resonance (SPR) measurements were performed 
on a Biacore T200 instrument equipped with an Ni-NTA chip (24). Approximately 2000 RU of 
5% PA nanodiscs were immobilized non-covalently using 100 mM NiSO4 flowed at 10 µL/s 
followed by a blank buffer injection of HEPES pH 7.4, 150 mM NaCl (HBS Buffer). Injections 
were performed in HBS buffer at a flow rate of 30 µL/min with an association time of 90 sec, 
dissociation time of 300 sec., and binding was measured in relative response units (RU) as 
described (44). Regeneration with EDTA was performed at flow rate 30 µL/s for 120 s using 100 
µM EDTA buffer. Proteins were injected using a series of 1:1 dilutions from highest concentration 
and steady state was obtained using GE BIAcore T200 evaluation software version 3.0 
(BIAevaluate). Proteins were injected using a series of 1:1 dilutions for Sec18 monomer, D1, D2 
and Sec18 hexamer with at least one concentration from each titration run in duplicate. Steady 
state data was exported using BiaEvaluate software into GraphPad Prism 7.00 for Windows, 
GraphPad Software (La Jolla, CA) and fit using either a one-site specific binding model or an IC50 
model generated using log[IPA] v. response (three parameters) equation.  
  
For SPR using attached liposome an L-1 liposome chip was used with liposome attached to a 
sample flow cell and no liposome to the reference flow cell.  Liposomes were attached after 
conditioning the chip with two injections of CHAPS (3-[(3-cholamidopropyl)-dimethylammonia]-
1-propan-sulfonate over both flow cells for 30 sec at 30 µL/min.  Each liposome capture was 
68 
 
regenerated when a different protein was flowed using 30 sec injections of 20 mM CHAPS at 5 
µL/min to clean the sensor chip. Proteins were attached freshly for each type of protein, where 
proteins were titrated in the presence and absence of IPA yielding IC50 and KD values. KD values 
to liposomes were performed at 30 µL/min with association of 70 sec and disassociation of 300 
sec for D1, 60 sec association and 300 sec dissociation for Sec18 monomer and hexamer, and 60 
µL/min for D2 with association 75 and disassociation of 225 sec. Results were exported from 
BIaEvaluate into Graphpad and fit via one-site specific binding model for each saturation curve 
yielding KD values for different constructs.   
  
Microscale thermophoresis – Thermophoresis measurements were performed using a Monolith 
NT.115 labeled thermophoresis machine (45). Sec18-His8 was labeled with Ni-NTA Atto 488 
according to the manufacturer’s protocol mixing 200 nM protein with 100 nM dye and allowing 
to sit at room temperature for 30 min followed by centrifugation. M.O. Control software was used 
for operation of MST. Target protein concentrations were 50 nM for all His-tag labeled proteins 
Sec18 monomer, Sec18 hexamer, PA nanodiscs, and PC nanodiscs. LED excitation power was set 
to 90% and MST set to high allowing 3 s prior to MST on to check for initial fluorescence 
differences, 25 s for thermophoresis, and 3 s for regeneration after MST off. Analysis was 
performed using M.O. Affinity Analysis Software as the difference between initial fluorescence 
measure in the first 5 s as compared with thermophoresis at 15 s. All measurements were 
performed in PBS buffer (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4, pH 
7.4) without Tween and binding affinity was generated using Graphpad Sigmoidal 4PL fit from 
points exported from M.O. Affinity Analysis software using KD Model with target concentration 
fixed at 50 nM generating bound, unbound, and fraction bound for export to Graphpad in order to 
estimate final KD.    
  
1,8-ANS Fluorescence Spectroscopy – ANS binding experiments were carried out as described 
previously (12). Reactions were performed in fluorescence assay buffer with 5 µM 1-anilino-8-
naphthalenesulfonate (ANS) (Cayman Chemical). Initial spectra were taken without protein to 
measure any background fluorescence from buffer or added lipids (ex. 350 nm, em. 390-620 nm). 
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His8-tagged Sec18 truncations containing the N-domain and D1-domains (N-D1), or D1 and D2 
domains (D1D2) were diluted in assay conditions and then added to the assay to the indicated 
concentration and incubated at 25°C for 5 min before spectra were obtained. Initial background 
fluorescence spectra for each lipid concentration were subtracted from final measurements.  
  
Limited Proteolysis – Cleavage reactions were carried out as described (12). Sec18-His8 (2 µM) 
was added to proteolysis buffer (20 mM HEPES pH 7.2, 150 mM NaCl, 2 mM ATP, 2 mM MgCl2) 
and incubated with indicated lipid or IPA concentration on ice for 5 min. Thrombin diluted in 1X 
HBS was added to assay tubes at indicated concentrations and incubated at 25°C for 30 min. 
Cleavage reactions were stopped with the addition of SDS sample buffer containing 1 mM PMSF. 
Samples were resolved with SDS-PAGE and gels were stained using Coomassie Blue. Gels were 
de-stained with methanol/acetic acid solution (50%/7%) and imaged using a ChemiDoc MP 
Imaging System (BioRad).  
  
Mass Spectrometry – Cleavage products from limited proteolysis experiments were excised from 
SDS-PAGE gels and submitted for LC-MS/MS performed and analyzed by Bioinformatics 
Solutions Inc. (Ontario, Canada).   
  
MD Simulations of Top Poses from Ensemble Scoring Function – A previously reported model of 
D1D2 by Starr, Sparks, Arango et al. was utilized for this study. The model was derived from a 
Cryo-EM structure of ATP-bound NSF complex (PDB 3J94 - chain A) containing residues 215-
737 (31). Molecular dynamics simulations were done using NAMD 2.12 (46), with the 
CHARMM36m force field (47). To maintain a constant pressure of 1 atm and temperature of 
310.15 K, Langevin dynamics and Langevin piston Nosé−Hoover methods were used respectively 
(48, 49). Particle mesh Ewald (PME) methods were used to calculate long-range electrostatic 
forces using 1 Å grid spacing (50, 51). Van der Waals interactions were evaluated with a cutoff of 
12 Å, and after 10 Å used a force-based switching scheme. Integration time step was set at 2 fs 
with the SETTLE algorithm (52) applied. VMD 1.9.3 was used for MD trajectory visualization 
and analysis (53). The D1-D2 monomer was equilibrated for 20ns using harmonic restraints on the 
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Cα atoms (0.05 kcal/mol/Å2), barring the previously modelled loops. The simulation was 
continued without restraints to 200 ns.   
  
Probing Binding Sites of IPA – To identify potential IPA, PA, and epirubicin interactions with D1-
D2 monomer, molecular ensemble docking of was done on D1-D2 monomer using AutoDock 
Vina (54). The previously mentioned equilibrium simulation of D1-D2 was used to fully sample 
the dynamics of D1-D2 for molecular docking, where snapshots were taken every 1000 ps of the 
200 ns trajectory. For each snapshot, an 80Å by 94Å by 108Å grid box was used to fully sample 
the entire structure. Each snapshot was docked with an exhaustiveness of 10, yielding a total of 
2000 IPA and PA docked poses, with the affinities of each pose obtained from the resultant log 
files. These poses where then clustered using a hybrid K-centers and K-medoids clustering 
algorithm using an RMSD method (55, 56) with which four main clusters where identified. Poses 
from each cluster provided by the ensemble docking from AutoDock Vina with the highest 
interquartile scores were selected for simulation. Selected poses were solvated and ionized to a 
NaCl concentration of 150 mM using the SOLVATE and AUTOIONIZE plugins within VMD 
respectively (53). These systems were simulated for 100 ns and were analyzed with VMD as well 
as MDAnalysis package (57, 58)  
  
Dynamic light scattering – A Malvern Zetasizer Nano ZS was used to measure both 100 nm 
extruded liposomes and water bath sonicated liposomes to compare 80/20 PC/PE liposomes to 
75/20/5 PC/PE/PA liposomes.  Liposomes created for co-floatation and binding experiments were 
measured exporting a frequency plot for size distribution, taking 3 separate measurements, and 
choosing a representative measurement. Liposomes were diluted to 5 µM in TBS (50 mM TRIS-
Cl pH 7.5, 150 mM NaCl) using a Zetasizer set with dispersant with a refractive index of 1.331 
for TBS, material of DPPC liposomes, and disposable cuvettes.  The presence of PA had no effect 
on the diameter of extruded liposomes (Fig. S2A).  Liposome floatation was performed as 
described above with 100 nm PA extruded liposomes in the presence or absence of 100 µM IPA.  
Approximate concentrations of liposome were performed using DLS and measuring kilocounts 
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per second (kcps) (59, 60). Scattering intensity Kcps values of liposomes before and after 
floatation were plotted on Y axis for each liposome type (Fig. S2B).  
  
Data Analysis and Statistics – Results are expressed as the mean ± S.E. Experimental replicates 
(n) is defined as the number of separate experiments with different batches of protein, liposomes, 
and nanodiscs. Where appropriate, significant differences were calculated using two-tailed 
unpaired t-tests. P values ≤0.05 were considered significant.   
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FIGURES AND TABLES 
Table 3.1 Binding affinities for Sec18 and its domains 
 












Figure 3.1. Small Molecule Candidates for Sec18 Binding and Priming Inhibition. (A). Left; 
Schematic of Sec18 with labeled domains (N, D1 and D2) in its monomeric (mSec18) and 
hexameric (hSec18) forms. Right; Schematic model of Sec18 mediated SNARE activation. Pah1 
is a PA phosphatase. Sec17/a-SNAP is the adaptor protein linking Sec18 to inactive cis-SNARE 
complexes. (Adapted from (12)). (B) Structures of IPA (7-Methyl-3-(4,5,6-trihydroxy-3-oxo-3H-







Figure 3.2. IPA and Epirubicin binding to Sec18. (A) Ligand Interaction Diagram of IPA 
binding to homology model of mSec18 and receptor grid for Box 3 of homology model of Sec18 
corresponding to Schrodinger Sitemap predicted site 3. Pi stacking indicated with red arrows H-
bonding including salt bridge between Lys159 and D374 hydrogen bonding with IPA. (B) Ligand 
Interaction Diagram of IPA binding to mSec18 corresponding to Schrodinger Sitemap predicted 
site 4. Salt bridge with Ser378 and IPA with arrow. (C) Ligand Interaction Diagram of Epirubicin 
binding to receptor grid for Box 3. (D) Ligand Interaction Diagram of Epirubicin binding to 
receptor grid for Box 4. (E) Bar graph depicting gscore of best IPA and Epirubicin poses 
corresponding to (Fig 3b-e) to boxes 3 and 4 indicated with lowest -DG using Schrodinger Glide 
and exported into GraphPad. (F) IPA cluster analysis displayed and edited with VMD for IPA to 
D1-D2 of NSF with D1 indicated with purple and D2 green and top 4 most populated clusters 
represented with dark grey for cluster 1, orange for box, light blue for box 3 and light gray for box 
4. (G) Epirubicin cluster analysis displayed and edited with VMD for Epirubicin to D1-D2 of NSF 
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Figure 3.3. Sec18 Binding Affinities IPA. a, Fluorescence MST of IPA binding to Sec18-His8 
labeled with Atto 488 Ni-NTA dye with fluorescence converted to fraction bound M.O. Affinity 
software and exported in Graphpad with KD of 3.84 µM ± 1.3 µM using log-inhibitor vs. response 
4 parameter equation and error using SEM (n=3). b, Label-free MST of IPA binding to unlabeled 
Sec18-His8 converted to fraction bound as in (Fig. 1a) with KD of 7.4 µM ± 3.7 µM µM using 
log-inhibitor vs. response 4 parameter equation error using SEM (n=3). c, SPR of IPA to Sec18-
His8 linked to a Ni-NTA biosensor chip at approximately 2000 RU with Response measured 
subtracting blank reference cell and relevant blank injections. Data exported from BiaEvaluate and 
into GraphPad and fit using a one-site specific binding model indicating a KD of ~4 µM. d, SPR 
sensorgrams of NiNTA captured D1 of ~ 2500 RU at corresponding PA injection concentrations 
with light blue 8 µM, magenta 4 µM, blue 2 µM and green 1 µM exported from BiaEvaluate and 
into Graphpad for depiction. KD measured by Kd/Ka 320 nM with ka of about 1700 M s-1. e, SPR 
sensorgrams of D2 to IPA as in (Fig. 2d) with KD ~1.1 µM with ka of about 1900 M s-1. f, SPR 





Figure 3.4. IPA competes for PA binding. a, Full length Sec18 were incubated with PA 
liposomes in the presence or absence of a dose response curve of IPA. After incubation the 
liposomes were re-isolated by floatation centrifugation, solubilized and resolved by SDS-PAGE. 
Bound Sec18 was detected by immunoblotting with anti-Sec18 antibody. Local quantification 
ImageLab 5.21 and density divided by input for each concentration plotted into Graphpad against 
Log[IPA], µM with IC50 of about 3.2 µM and Ki of (~1614 nM). b, SPR using NiNTA chip 
captured with approximately ~1000 RU fresh 5% PA nanodiscs titrated with mSec18-GST or N-
GST. Binding was performed by incubating a fixed protein concentration with a titration of IPA. 
IC50 values were determined from the sensorgrams and presented as a bar graph. c, SPR of 7XHis 
tagged mSec18, hSec18, D1 and D2 constructs binding to 0.8 µm PA liposomes at about 4000 RU 
captured to an L1 biosensor chip exported and fit as in (Fig 2c) yielding KD values for D1 (781 
nM ± 110 nM), D2 (866 nM ± 669 nM), and mSec18 (505 nM ± 267 nM). d, SPR competition of 
Sec18 constructs binding to PA liposomes as in (Fig 2c) titrated with IPA and exported and fit as 
in Figure 2b and Ki of D1 (~172 nM), D2 (~555 nM), and mSec18 (1533 nM). e, IPA competition 
of PA liposome binding by GST-DEP and quantitation of three trials exported and analyzed as in 
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Figure 3.5. IPA Inhibits Vacuole Fusion at the SNARE Priming Stage. Figure 5. Liposome 
diameter affects IPA inhibition of Sec18 binding to PA. (A) Extruded PA liposomes of 0.1 μm, 
0.4 μm and 0.8 μm were bound to L1 biosensor chips. Sec18 was titrated to give a with KD 1600 
± 933 nM, 1020 ± 549 nM and 673 ± 239 nM for 0.1, 0.4 and 0.8 μm diameter liposomes, 
respectively. Error bars representing SEM (n=3). (B) As in panel A, Sec18 was flowed over PA 
liposomes attached to L1 chips in the presence or absence of 100 μM IPA. The difference in RU 
of Sec18 binding to liposomes in the presence of IPA was calculated relative to the maximum 
Sec18 bound in the absence of IPA. The bar graph represents the Mean values of inhibition with 
individual points shown. The error bars represent SEM (n=3). (C-D) Liposome integrity in the 
presence of IPA was tested by Calcein release. PA Liposomes were extruded in the presence of 
100 mM Calcein, a concentration that leads to fluorescence quenching. Calcein containing 
liposomes were incubated with buffer, Triton X-100 or a dosage curve of IPA. Liposome damage, 







Figure 3.6. IPA does not induce a conformation change in Sec18. a, N-D1 and N-D2 (0.5 µM) 
was incubated with increasing concentrations of C8-PA in the presence of ANS (5 µM) and 
fluorescence spectra were taken. A representative spectrum for each lipid tested is shown with n=3 
for all data shown. b, Sec18-His8 was incubated with buffer, IPA (a), or C8-PA (b) before 
incubation with increasing concentrations of thrombin for 30 min. Reactions were stopped by 
adding SDS-PAGE loading buffer. Sec18 digests were resolved by SDS-PAGE and stained with 





Figure 3.7. IPA and conformation changes in full length Sec18. Sec18-His8 (A-B), N-D1 (C-
D) and D1D2 (D-E) samples were incubated with buffer, IPA, or C8-PA before incubation with 
increasing concentrations of thrombin for 30 min. Reactions were stopped by adding SDS-PAGE 
loading buffer. Protein digests were resolved by SDS-PAGE and stained with One-Step BlueÒ 
Protein Gel Stain (Biotium). Quantitation was determined for the relative amounts of un-cleaved 
protein. n=3 for all data shown. Mr relative molecular mass markers. *, p<0.05; **, p<0.01; *** 
p<0.001; ****, p<0.0001. Schematics represent Sec18, N-D1 and D1-D2. Cleavage sites are 






Figure 3.8. IPA blocks the effect of PA on Sec18 degradation by thrombin. Full length Sec18 
was incu-bated with 100 μM C8-PA alone or 100 μM IPA followed by 100 μM C8-PA, after which 
the samples were incubated with thrombin for 30 min. Samples were mixed with SDS loading 
buffer and resolved by SDS-PAGE and visualized with One-Step BlueÒ Protein Gel Stain. 
Quantitation was determined for the relative amounts of un-cleaved protein. n=3 for data shown. 
Mr relative molecular mass markers. **, p<0.01; ****, p<0.0001. Major degradation products are 





Figure 3.9. ANS Fluorescence of Sec18 domains bound to lipids. N-D1 (0.5μM) was incubated 
with dos-age curves of C8-PA (A)or C8-PI(4,5)P2(B)and 5 μM ANS. Fluorescence was measured 
by exciting at 390 nm and scanning a range of emission wavelengths. (C-D) D1-D2 (0.5 μM) was 
incubated with C8-PA or or C8-PI(4,5)P2, and 5 μM ANS. Fluorescence was detected as above. 
(E) Quantitation of maximum fluorescence measurements at each concentration of lipid. Error bars 





Figure 3.10. Molecular Dynamics of PA, IPA, and Epirubicin. a, Average RMSD of PA (n=2) 
100 ns simulation. b, Average RMSD of Epirubicin (n=4) 100 ns simulation. c, Number of waters 
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ANS, 8anilino-1-naphthalenesulfonic acid; DAG, diacylglycerol; DEP, Dishevelled, Egl-10, and 
pleckstein domain; diC8, dioctanoyl; C8-PA, 1,2-dioctanoyl-snglycero-3-phosphate; GST, 
glutathione S-transferase; MD, molecular dynamics; MST, microscale thermophoresis; Ni-NTA, 
nickel-nitrilotriacetic acid; NEM, N-ethylmaleimide; NSF, NEM-sensitive factor; PA, 
phosphatidic acid; PC, phosphatidylcholine; PDB, Protein Data Bank; PE, 
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Chapter 4: Probing Multi-ligand Sorting Receptor by PIP3 Through Discovery of Site 
Specific Molecules to Sortilin 
 
ABSTRACT 
Sortilin regulates hepatic exocytosis and endocytosis of ApoB containing lipoproteins (ApoB-Lp) 
and mediates the secretion of the subtilase PCSK9. To elucidate connections between these 
pathways, we previously identified a small molecule (cpd984) that binds to a non-canonical site 
on Sortilin. In hepatic cells cpd984 augments ApoB-Lp secretion, increases cellular PCSK9 levels, 
and reduces LDLR expression indicative of reduced secretion of PCSK9. We have shown that 
insulin-induced ApoB-Lp degradation occurs through Vps34-dependent autophagy. Here we show 
that the specific Vps34 inhibitor PIK-III enhances ApoB-100 secretion, reducing cellular levels of 
PCSK9 and Sortilin resulting in increased LDLR expression, which implicates a role for autophagy 
in PCSK9 secretion. Results suggest that Sortilin is central to both PCSK9 and ApoB-100 
secretion. Finally, we found that cpd984 in yeast blocks CPY secretion while increasing vacuolar 
homotypic fusion in a Vps10-dependent manner, indicating an evolutionarily conserved 
mechanism required for lysosomal protease trafficking. 
 
INTRODUCTION 
Trafficking pathways in yeast have been studied extensively as models of eukaryotic biology, 
which have in turn have been informative for discoveries in mammals related to human disease 1. 
Vps10 in yeast traffics the lysosomal protease CPY (carboxypeptidase) from the Golgi to the 
vacuole in an anteretrograde fashion and Vps10 recycles back to the Golgi via the retromer. Vps10 
orthologue Sortilin in mammals traffics proteins from the Golgi where it is activated by furin 
mediated cleavage of its prodomain 2. Sortilin is responsible for trafficking its ligands between 
secretory pathways and lysosomal protein pathways 3. Vps10 and its mammalian counterpart 
Sortilin release cargo upon entering acidic endosomal compartments, which may be followed by 
dimerization of the luminal  -propeller domains of Sortilin. Subsequently, Vps10/Sortilin can be 
recycled back to the Golgi by the Retromer pathway, which could be mediated by dimerization 4. 
In higher eukaryotes, Sortilin is expressed in diverse cell types where it serves as a tissue specific 
91 
 
cargo receptor. In neuronal cells, Sortilin participates in the secretion of neurotensin (NT) and 
other neuromodulators 5, while in adipose tissue, Sortilin mediates the expression of the type 4 
glucose transporter Glut4 at the plasma membrane 6. In hepatic cells, the Sortilin receptor primarily 
regulates ApoB containing lipoproteins (Apo-Lp) and the protease PCSK9 (proprotein convertase 
subtilisin-kexin type 9). When secreted, PCSK9 binds to LDL receptor (LDLR), which targets 
both LDLR and PCSK9 for lysosomal degradation 7. 
 
Through GWAS analysis, SORT1 mutations have been identified as candidates that correlate 
mutations in Sortilin with cardiovascular disease outcomes 8,9. Sortilin has complex relationships 
with lipoprotein metabolism 10 and in lipid accumulation in arteries 11. At the plasma membrane, 
Sortilin is found in Clathrin-coated pits similar to the LDLR, both of which bind ApoB-Lp 12. 
Differences in function and ligand specificity for the two receptors is unknown. Further 
complicating understanding of Sortilin function is its additional role in hepatic VLDL secretion 
where hepatic knockouts of Sortilin have been described to either increase or decrease VLDL 
secretion 13. Sortilin isa multiligand receptor that can interact with the various ligands found on 
VLDL including B100 14, ApoE 15,16, and PI(3,4,5)P3 
17. Circulating VLDL content of PI(3,4,5)P3 
is enriched as compared to HDL and LDL17. The paradox for the ability of Sortilin to both increase 
or decrease VLDL secretion could relate to the relative concentration and position of ligands on 
the VLDL surface. Presence of PI(3,4,5)P3 on lipoproteins relates to insulin signaling where 
PI(3,4,5)P3 is considered as a principal mediator of insulin signal transduction, which could 
provide a mechanism for shortterm modulation of VLDL interaction with Sortilin 18 19.   
 
An additional lipoprotein related ligand for Sortilin is the subtilase PCSK9, which has been shown 
by SPR to bind to human Sortilin with high affinity 20. Importantly, this study showed that 
neurotensin (NT), a natural substrate for Sortilin, did not inhibit PCSK9 binding, even at saturating 
concentrations 21. It has been proposed that PCSK9 is chaperoned for secretion by Sortilin. Once 
PCSK9 is released by sortilin extracellularly, it binds to LDLR resulting in degradation of the 
associated complex resulting in decreased expression of LDLR on the cell surface as LDLR bound 
to PCSK9 results in degradation of both PCSK9 and LDLR at the lysosome. We now show that 
PCSK9 secretion can be modulated by targeting Sortilin. We hypothesize that the relative secretion 
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of Sortilin and PCSK9 can be co-regulated in hepatocytes by VLDL composition and by non-
canonical binding of molecules to Site-2 of Sortilin. We suggest that this pathway is a complex 
and dynamic system for regulating ApoB-100 metabolism, which takes into account the balance 
of cellular intake (LDLR and VLDLR) and secretion of VLDL, a very low-density progenitor of 
LDL. We further show that the non-canonical Site-2 of Sortilin. may have  evolved from primitive 
systems for protease trafficking in yeast involving Vps10 with similarities for carboxypeptidase 
(CPY) and PCSK9 trafficking 22. 
 
Results presented suggest a potential alternative to current strategies targeting inhibition of the  
binding of PCSK9 to the LDL receptor (LDLR) 23. We hypothesize that using Site-2 directed 
Sortilin binding molecules such as cpd984, hepatic LDLR expression and VLDL secretion could 
be increase under appropriate clinical settings. Furthermore, approaches could be developed to 
selectively regulate involved pathways by utilizing both sites of Sortilin, as we now show the 
inverse results of Site-1 and Site-2 specific Sortilin molecules 24. 
 
RESULTS 
Cpd984 and Cpd541 Bind at Different Locations of Human Sortilin 
Our previous studies defined the interaction of cpd984 with Site-2 on Sortilin and its effects on 
NT binding and VLDL secretion 24. Here we tested whether cpd984 in combination with cpd541, 
a Site-1 directed small molecule could be used to examine the relationship between Sites-1 and -2 
on Sortilin. In Figure 4.1a, we show SPR results of a titration of cpd984 concentrations binding 
to Sortilin. This provides strong evidence that cpd984 binds Sortilin with high affinity, having a 
KD of 118 ± 38 nM (Fig. 4.1a). Next, we determined the binding affinity of Sortilin for cpd541, 
which we determined has a KD of 6.9 ± 1.1 µM for Sortilin (Fig. 4.1b). To determine whether 
binding Site-2 is independent of Site-1, we measured the binding of cpd984 in the presence of a 
nearly saturating concentration of 10 µM cpd541. We found that cpd984 bound to Sortilin with a 
similar affinity in the presence of 10 µM cpd541 as in the absence of cpd541 (Fig. 4.1c). Results 
are consistent with our previous study showing that cpd984 bound Sortilin in the presence of C-




Using ensemble molecular docking we showed that cpd984 binds to regions of Sortilin comprising 
Site-2 (Fig. 4.1d), with a higher percentage than cpd541 (Fig. 4.1e). Furthermore, we found that 
the protonated carboxylate on cpd541 did not affect its preferential clustering in Site-1 versus the 
more hydrophobic Site-2. In parallel, we found that cpd984 with an unprotonated pentaamine ring 
has a basic pH of 8.4 (± 1.2), as determined by ab initio calculations using Jaguar 25. The 
protonation state of cpd984 had no effect on Site-2 binding, whereas cpd541 protonation state of 
the carboxylate resulted in a slight enrichment of cpd541 to Site 2 of Sortilin (Fig. 4.1e). To test 
whether pH dependent conformational changes impacted Site-1 or Site-2 binding, using 
Schrodinger Glide XP, we computationally docked both cpd541 and cpd984 in both Site-1 and 
Site-2 of a crystal structure of Sortilin at neutral pH (PDB ID: 4PO7) and acidic pH (PDB ID: 
6EHO) as shown in Figure 4.1f. Cpd541 showed dramatically reduced binding to Site-1 of Sortilin 
as compared to cpd984, indicating that cpd541 is similar to other Site-1 substrates that  bind to the 
NT binding site of Sortilin, and lose affinity at low pH 26. Furthermore, docking results confirm 
that cpd984 shows little discrimination between acidic and neutral pH structure of Sortilin. 
 
Using molecular dynamics (MD), six 50 ns simulations were run for cpd541 and cpd984 for both 
Sites-1 and -2 comprising 24 simulations over 1 microsecond in total (Fig. 4.2a). The three best 
binding poses of cpd984 to Site-1 were chosen using ensemble poses generated from clusters of 
Site-1, whereas the three best poses with a salt bridge from cpd541 to Arg292 with the best 
autodock docking score were chosen and all three poses run in duplicate Figure 4.1d.  For Site-2, 
the cpd984 pose comprising the closest match to ourpreviously determined  pose of cpd984  to 
Site-2 was used, whereas for cpd541 the three best poses of cpd541 to Site 2 were chosen24. Results 
and analysis of the MD simulations are presented in Figure 4.2. Cpd984 (Fig. 4.2a) and cpd541 
(Fig. 4.2d) average distances from Arg292 in Site-1 and Leu539 in Site-2 are given. We found 
that cpd984 remained within 10 Å from Leu539 throughout the simulation (Fig 4.2a) 24. In 
contrast, simulations of cpd984 to Site-1 showed that it did not stay within 10 Å of R292 for Site-
1. In addition to the stable association of cpd984 with Site-2, we found that cpd984 buries itself 
into the hydrophobic Sortilin beta propeller, between blades 1 and 10/Using F555 as a reference 
amino acid nearing the end of blade 10 of Sortilin, we show that cpd984 on average over six 50 ns 
simulations comes closer to this hydrophobic cavity over time (Fig. 4.2b). A representative 
94 
 
endpoint of one of these simulations is presented in a ligand interaction diagram of cpd984 is 
presented in Figure 4.2c. Taken together, we hypothesize that the hydrophobic cpd984 is more 
likely to stay bound to Site-2 than to Site-1. Additionally, as cpd984 does not carry a negative 
charge at acidic or neutral pH, and has greater association with Site-2 than Site-1 of Sortilin, it is 
likely that cpd984 binding to Sortilin is pH independent in the cell (Fig. 4.1e, f). 
 
Regarding cpd541, we hypothesized that it requires some electrostatic binding to form a salt bridge 
with Arg292 and stably interact with Site-1 via its carboxylate. In Figure 4.2d, we found that 
cpd541 did not stay as tightly associated to Site-2 of Sortilin as compared cpd984. In contrast, 
cpd541 stably associated with Site-1 more than Site-2. That said, not all cpd541 simulations 
remained associated with R292. A fraction of cpd541 simulations started with a salt bridge to 
Arg292, eventually stably forming a salt bridge with Lys227 as depicted in Figure 4.2f depicting 
one of the final frames of a cpd541 simulation to Site-1 of Sortilin.  
In Figure 4.2e, we show the fraction time bound over the course of all 24 50 ns simulations as a 
function of the amount of frames of the simulations as a whole, where either cpd541 or cpd984 
stayed within 3.5 Å of a given residue of Sortilin, over the course of all 50,000 frames of the 
simulation, with each frame representing 1 ps. It is clear that cpd984 had a greater fraction bound 
time than cpd541 in Site-2 of Sortilin, and that cpd541 had a greater fraction time bound than 
cpd541 to Site-1 (Fig. 4.2e). Furthermore, the residues of interest for these interactions 
corresponded well to the NT peptide binding modes of Sortilin from PDB ID: 4PO7, which we 
have hypothesized represents the full NT peptide across the Sortilin cavity connecting Site-1 and 
Site-2 of Sortilin 24.  
 
Sortilin-targeting Small Molecule alters NT Binding and ApoB Secretion 
Using SPR to monitor NT binding to Sortilin we found that cpd541 competed for NT binding to 
Sortilin in a dose dependent fashion (Fig. 4.3a). In contrast, we now show that cpd984 enhanced 
NT binding to Sortilin in a dose dependent fashion 24. As NT binding has been shown to be mainly 
guided by Site-1, we hypothesize that cpd541 as an inhibitor most likely binds to NT bindingSite-
1 of Sortilin 27. Next, we examined the effects of these compounds on ApoB secretion. This was 
done with different cell lines in which Sortilin levels were differentially reduced with siRNA. 
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Sortilin knockdown cell lines 1-4 expressed 95%, 70%, 40% and 10% of Sortilin, respectively, 
relative to the scrambled siRNA control cells (Fig. 4.3b). As previously reported, cpd984 enhanced 
ApoB secretion in all cell lines, in proportion to the amount of Sortilin expressed (Fig. 3b). In 
contrast, cpd541 reduced ApoB secretion consistent with Site-1 being the primary binding region 
of Sortilin for VLDL. When administered together, cpd984 and cpd541 restored VLDL secretion 
to levels near the untreated control (Fig. 4.3c). This suggests that binding Site-2 allosterically 
regulates Site-1 binding. 
 
The Vps34-Specific Inhibitor PIK-III blocks Autophagy and Sortilin Function 
Previous studies of Sortilin indicate a specialized autophagy responsible for insulin-dependent 
degradation of ApoB in a manner independent of p62 28,29. To test effects of Vps34 specific effects 
on trafficking regulation of VLDL and LDLR we used the Vps34-specific inhibitor PIK-III in lieu 
of pan-PI 3-Kinase inhibitors such as wortmannin 30. In order to determine efficacy of PIKIII on 
autophagy as a control, we measured the autophagy markers LC3-I, LC3-II, and p62 in the 
presence or absence of wortmannin or PIKIII. Basal autophagic flux was blocked with E/P (E-64d 
and Pepstatin) 31,32, or HCQ (hydroxychloroquine) 33,34, or left untreated. Autophagy activation 
was detected by presence or absence of LC3-II. We found that LC3-II production was inhibited 
completely under all three conditions with PIK-III, whereas wortmannin had no effect (Fig. 4.4a). 
Furthermore, it appears that neither PIK-III nor wortmannin affected p62 levels under autophagic 
conditions similar to a previous report suggesting a selective form of autophagy associated with 
Sortilin 28. As a measure of insulin-triggered autophagy, we tested whether PIK-III had an effect 
on the phospho-AKT pathway. We found that PIK-III, unlike wortmannin, failed to inhibit 
phospho-AKT production (Fig. 4.4b).  
 
PIK-III Alters PCSK9 Secretion and LDLR Surface Expression 
After characterizing PIKIII as an autophagy inhibitor, we tested for its effects on Sortilin mediated 
trafficking by monitoring both VLDL secretion and PCSK9 regulation of LDLR in the presence 
and absence of wortmannin and PIKIII. Our results indicate that PIK-III affected both VLDL 
secretion (Fig. 4.4c) and LDLR expression (Fig. 4.4d). It appears from Figure 4.4c that total ApoB 
increased with PIKIII in both the cell and the media. We hypothesize that as PIKIII inhibits 
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autophagic degradation of ApoB, it would then increase the total amount of ApoB available, 
therefore, we would expect more ApoB shifted towards secretion while the intracellular increase 
in ApoB was due to lack of autophagic degradation. Immunoblotting for intracellular pools of 
PCSK9, Sortilin, and LDLR showed a decrease in LDLR expression, and reduced levels of Sortilin 
and PCSK9 (Fig. 4.4d). We hypothesize that decreased intracellular PCSK9 is consistent with 
increased PCSK9 secretion, resulting in decreased LDLR expression. The decreased intracellular 
Sortilin is likely due to the requirement for more Sortilin to be diverted to secretion due to 
increased ApoB availability. 
 
Effect of cpd541 and cpd984 on the Sortilin-VLDL-PCSK9 Trafficking Pathway. 
We further tested the effect of modulating Sortilin trafficking through defined Site-1 and Site-2 
molecules. We found that the Site-2 cpd984 enhanced LDLR expression (Fig. 4.5a), whereas 
cpd541 had little effect on PCSK9. We hypothesized that PCSK9 binds to Site-2, which could 
explain why cpd984 was effective in modulating PCSK9 as opposed to cpd541. Using the protein-
protein docking prediction software ClusPro, we docked PDB ID: 4PO7 Sortilin to PDB ID: 2P4E 
PCSK9, removing the NT fragments of 4PO7 prior to simulation. All 10 clusters showed PCSK9 
binding to Blade-1 of Sortilin (Fig. 4.5b), and selected the top 3 poses with the lowest overall 
predicted G. We ran the three generated clusters for 25 ns each and analyzed both Sortilin and 
PCSK9 contact points for binding approximated by having a distance of less than 3.5 Angstroms 
between the two proteins. This showed that the residues of Sortilin closest to PCSK9 over 
throughout multiple trajectories remained to be adjacent to Site-2 or on the outside of the Sortilin 
cavity opposite Site-2. In Figure 4.5d, we show a root-mean-squared fluctuation (RMSF) analysis 
of these same trajectories for Sortilin. Residue analysis (Fig. 4.5c), and RMSF analysis (Fig. 4.5e) 
were additionally performed for PCSK9 using residues at its interface with LDLR for reference 
utilizing a 5 ns MD simulation of PCSK9 to LDLR from PDB ID: 3P5C . All results are consistent 
with PCSK9 binding to Site-2. 
 
Characterization of VLDL and LDL Sortilin Affinity  
Having concluded previously that PI(3,4,5)P3 binds to Site-1 
17, we tested in vitro binding using 
SPR to determine the effect of cpd541 and cpd984 on Sortilin binding of PI(3,4,5)P3. First, we 
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found that diC8-PI(3,4,5)P3 bound with high affinity to crosslinked Sortilin with a KD of 4.2 µM ± 
380 nM (Fig. 4.6a). When we ran the same diC8-PI(3,4,5)P3 concentration curves in the presence 
of 10 µM cpd541 and 10 µM cpd984, we found that cpd541 abolished PI(3,4,5)P3 binding, whereas 
cpd984 enhanced diC8-PI(3,4,5)P3 binding about 10-fold to Sortilin with a KD of 474 nM ± 85 
nM. To determine if these effects held true for more native forms of PI(3,4,5)P3, we used nanodiscs 
containing 2.5% PI(3,4,5)P3Sortilin bound nanodiscs with an increased binding affinity over diC8-
PI(3,4,5)P3 for Sortilin with a KD of 55 nM ± 13 nM indicating importance for the lipid membrane 
to Sortilin binding. Similarly to diC8-PI(3,4,5)P3, the affinity of this interaction was enhanced 
about 10-fold by cpd984 to a KD of 5.4 nM ± 0.8 nM (Fig. 4.6b). 
 
We previously showed that circulating VLDL contains more PI(3,4,5)P3 than LDL 
17. Using these 
same fractions, we characterized rat derived circulating VLDL and LDL binding to Sortilin using 
SPR and MST. Here we show that rat VLDL bound Sortilin with a KD of ~4 nM, an order of 
magnitude higher relative to binding LDL with a KD of 54-74 nM. We hypothesize that this was 
due to differences in particle composition, where VLDL acquired PI(3,4,5)P3 during the co-
synthesis with ApoB. (Fig. 4.6d,e). These data suggest the differences between LDL and VLDL 
binding was independent of ApoB, as both particle types contain the protein, suggesting a primary 
difference was the presence of PI(3,4,5)P3.  
 
Sortilin Small Molecule Effect in Yeast 
The yeast gene VPS10 encodes the type I transmembrane receptor for carboxypeptidase Y (CPY) 
that cycles between the late Golgi and the prevacuolar compartment 22,35. The CPY hydrolase 
enters the ER as an inactive zymogen and is modified by four N-linked polysaccharides forming 
p1CPY (67 kDa) 36. Thereafter, p1CPY transits through the Golgi where polysaccharides are 
extended to form the p2CPY precursor (69 kDa). p2CPY is transported from late Golgi in vesicles 
containing the subtilase Kex2, and is subsequently delivered to the vacuole. Upon arrival, the 
amino pro-segment of p2CPY is cleaved to yield enzymatically active mature CPY or mCPY (61 
kDa). Similar to Sortilin, Vps10 has been shown to have multiple binding sites for different ligands 
in yeast, however, unlike Sortilin, Vps10 contains two protein sorting domains making Vps10 




We hypothesized that Sortilin trafficking of PCSK9 should share consistencies with Vps10 sorting 
of CPY, reasoning that the mechanism for regulation of trafficking of proteases destined for the 
lysosome or vacuole could help elucidate Sortilin cellular itinerary for other ligands such as 
VLDL-ApoB. First, we deleted VPS10 from our fusion tester yeast strains DKY6281 and BJ3505 
and compared vacuolar levels of CPY and the late endosomal/lysosomal rab GTPase Ypt7. In 
Figure 4.7a we show immunoblots of isolated vacuoles from vps10 yeast and their parent strains. 
These results indicate that CPY at the vacuole was reduced in the absence of Vps10 in both strains.  
 
Like PCSK9, we assume that increases in CPY at the vacuole, correspond with decreases in 
secretion of CPY. We used a classical technique to characterize trafficking defects in response to 
cpd984 38. To test if a Site-2 homologous area was present on Vps10, we treated wild type yeast 
cells with cpd984 and measured CPY secretion. We found that cells treated with 20 µM cpd984 
accumulated substantially more CPY at the yeast vacuole relative to the untreated control (Fig. 
4.7b). To test whether the increase in vacuolar CPY correlated to a decrease in secreted CPY 
stores, we treated individual yeast cultures with a concentration curve of cpd984. As shown in 
Figure 7c, secreted CPY was reduced with increased cpd984 concentrations. Together these data 
showed that a Site-2-like domain may be present on Vps10.  
 
Finally, we hypothesized that altered trafficking to the vacuole via Vps10 increases in vacuolar 
CPY due to cpd984 could alter vacuolar homotypic fusion as a measure for increased trafficking 
to lysosomes. In vitro vacuole fusion assays showed that cpd984 administration resulted in dose 
dependent increases in fusion of WT vacuoles, while no effect was seen with vps10 vacuoles, 
suggesting that proteins responsible for changes in fusogenicity may depend on Vps10 (Fig. 4.7d). 
This lends support to a hypothesis that cpd984 enhances Vps34 recruitment resulting in increased 
trafficking to the lysosome as a potential mechanism.   
 
DISCUSSION 
The endocytic pathway for ApoB-Lp uptake by LDLR in hepatocytes has been studied extensively 
and forms much of the basis for current therapies controlling high LDL cholesterol in humans 39. 
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Little is known about the role of Sortilin in this process or how the relative concentrations of these 
receptors are regulated by Sortilin in this pathway 7,10. In this study we undertook to further 
examine the role of Sortilin in LDL/VLDL trafficking. These data show that Sortilin binds VLDL 
with higher affinity compared to LDL (Fig. 4.6c,d). We speculate this to be the result of increased 
ligands for Sortilin on the VLDL surface other than ApoB-100, e.g. PI(3,4,5)P3 or ApoE, in 
contrast to decreased alternative ligands for LDL other than ApoB-100 17,40. 
 
Considering that PCSK9 is an additional ligand for Sortilin-mediated secretion in hepatocytes 7, 
we further explored the effect of cpd984 on PCSK9 binding to Sortilin. Using functional endpoints 
in McA cells we demonstrated that cpd984 treated cells retained PCSK9 (Fig. 4.5a) resulting in 
increased expression of LDLR. The absence of these effects with the Site-1 ligand cpd541 suggests 
Site-2 mediates this function. These results are consistent with the hypothesis that Site-2 is the 
primary region of Sortilin for PCSK9 in chaperoning its secretion. Furthermore, we showed that 
VLDL secretion is inversely modulated by administration of these two compounds (Fig. 4.3c), 
thatboth cpd effects  depend on Sortilin expression levels (Fig. 4.3b), and that when both sites are 
occupied affects on VLDL secretion are attenuated (Fig. 4.3c). This indicates the potential for site 
specific modulation of sortilin chaperone activity. 
 
Regarding NT binding to Sortilin, we showed that cpd541 inhibits NT binding whereas cpd984 
enhances binding (Fig. 4.3a). Results suggest a potential allosteric effect of Site-2 binding on 
VLDL binding to Site-1, resulting in increased secretion (Fig. 4.3b,c). Sortilin plays a central role 
in hepatic ApoB-Lp metabolism, yet its exact role remains enigmatic 13. The questions that remain 
are: 1) How do Sortilin knockdowns both increase and decrease hepatic VLDL secretion? 10; 2) 
Do separate VLDL ligands interact with one another when binding to Sortilin?; and 3) How 
important is Sortilin in mediating ApoB-Lp endocytosis through clathrin coated vesicles? 
Considering the complexity of these questions, we propose a model where Sortilin contains at least 
two interactive sites for ligand binding.  
 
In addition to mediating ApoB-Lp secretion, Sortilin has a significant role in ApoB degradation 
by the lysosome 41. Our previous work showed that blocking autophagy prevents insulin signaling 
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from suppressing ApoB secretion. Whether insulin dependent autophagy is merely an 
accumulation of basal autophagy is unknown, however insulin-dependent PI(3,4,5)P3 production 
its incorporation into VLDL leads us to posit that the production of this lipid diverts ApoB-Lp to 
the autophagic pathway. We further demonstrated that autophagy regulates PCSK9, Sortilin and 
LDLR levels (Fig. 4.4c,d). This process is not dependent on the production of pAKT triggered by 
insulin, as PIK-III failed to block AKT phosphorylation (Fig. 4.4b) 30. The reduction in LDLR, 
Sortilin and PCSK9 in the presence of PIK-III suggests that loss of autophagy results in increased 
secretion of Sortilin and PCSK9 with resultant PCSK9-mediated reduction in LDLR. Results 
suggest loss of autophagy affects Sortilin related processes involving both Site-2 and Site-1.   
 
Considering the importance of Site-2 in hepatic ApoB-Lp metabolism, we speculated that the Site-
2 related pathways for PCSK9 and ApoB-Lp may be conserved in other cell types with some 
probability that it could have evolved from a primitive pathway present in yeast. The mechanistic 
role of the yeast CPY protease receptor Vps10, the ancestor of Sortilin, is well well-documented, 
and also involves at least two ligand binding domains 42. We used cpd984 to ask whether it might 
modulate CPY trafficking as it had with Sortilin with respect to the protease PCSK9. Indeed, 
treating yeast with cpd984 resulted in decreased CPY secretion while increasing its intracellular 
pool, suggesting CPY sorting is a parallel pathway to PCSK9 sorting as shown by its accumulation 
at the vacuole and decrease extracellularly (Fig. 4.7b,c).  It appears that these effects are Vps10 
dependent as fusion increases with cpd984 were attenuated in vps10 strains (Fig. 4.7d).  
 
These studies demonstrate a complex interconnected regulatory system for hepatic lipoprotein 
metabolism based on evolution of Vps10. Considerable research will be required to completely 
define this mode of regulation. Considering the complexity of this system, we believe that our 
observations on Sortilin regulation in hepatocytes and yeast may serve as a paradigm for Sortilin 
trafficking in other cell types such as neuronal and adipose. Implications of these studies may also 
have impact on understanding other Sortilin related processes including insulin secretion 8,24,43, 
Glut4 transport 44–47, and plaque formation in Alzheimer’s 48–50 as well as serving as a model for 
function of other Vps10 homologues such as Vth1, Vth2, and YN94 or Sortilin homologues such 
as SORCS and SORLA involved in similar processes as Sortilin. Understanding and delineating 
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these protein functions should improve our understanding of the complex regulation of proteins 
involved in Vps10 family sorting pathways 51,52.   
 
METHODS 
Cell culture, materials and reagents 
McArdle RH-7777 cells (McA cells) were cultured as previously described in serum containing 
complete Dulbecco’s Modified Eagle’s Medium (cDMEM) 43,53. To induce insulin sensitivity, 
McA cells at 50-60% confluency were incubated for 18 h in serum-free media consisting of 
DMEM containing 1% (w/v) BSA (1% BSA/DMEM). Human Sortilin (Sortilin) (Ser78-Asn755) 
with C-terminal 6-His tag was from R&D Systems, Inc., (Minneapolis, MN). Plasma from fasted 
Sprague Dawley rats (BioreclamationIVT, Westbury, NY) was used to prepare VLDL ApoB 
standards. Mouse monoclonal antibody to rat B100 was prepared in our laboratory and 
characterized previously 54. Rabbit anti-Sortilin antibody was from GeneTex (GTX54854, Irvine, 
CA), BD Medical (A311709, Franklin Lakes, NJ) or from Abcam (ab16640, Cambridge, MA). 
Rabbit polyclonal PCSK9 and LDLR antibody was from LSBio (Seattle, WA). Mouse anti-
glyceraldehyde phosphate dehydrogenase (GAPDH) from Santa Cruz Biotechnology. Rabbit anti-
p62/SQSTM1 was from (Medical & Biological Laboratories, Nagoya, Japan) and anti-LC3 from 
(MBL International, Woburn, MA). Lipofectamine 2000, Plus™ Reagent, and rabbit anti-Vps34 
antibody were from Invitrogen/ThermoFisher. Anti-rabbit and anti-mouse horseradish peroxidase 
(HRP)-linked IgG and Hyperfilm™ were purchased from GE Healthcare. Rabbit anti-p-AKT 
(9271) and rabbit anti-AKT (9272) were from Cell Signaling Technology (Danvers, MA). 
Antibody against yeast Ypt7 and actin were previously described 55, and CPY (10A5B5, 
ThermoFisher). Mouse anti-pY Platinum 4G10 was from EMD Millipore (Temecula, CA). 
Horseradish peroxidase linked donkey anti-rabbit IgG (NA9340), sheep anti-mouse IgG 
(NXA931) and ECL Prime Western Blotting Detection Reagent (RPN2232) were from GE 
Healthcare. All other materials and reagents were essentially as described previously 53. diC8-
PI(3,4,5)P3 (1,2-dioctanoyl-phosphatidylinositol 3,4,5-triphosphate) was from Echelon Inc. 
Wortmannin was from Sigma Chemical Corp and 4'-(cyclopropylmethyl)-N2-4-pyridinyl-[4,5'-




(cpd984) and compound 54122218 [2-([(1R)-1-phenylethyl]aminocarbonyl)phenyl]amino}acetic 
acid were obtained from ChemBridge Corp. (San Diego, CA). Stock solutions of cpd984 and 





Rat hepatocytes (RH) were isolated from Sprague-Dawley rat livers, and were cultured on 
collagen-coated dishes in Waymouth's 751/1 medium containing 0.2% (w/v) BSA as described 
previously 56. Wild-type McA cells were maintained in culture in complete DMEM (cDMEM) 53. 
Inhibitors were used at reported concentrations for cpd984 and cpd541. PIK-III was administered 
at 1 µM and wortmannin administered 10 µM.  Inhibitors were validated in RH where cell toxicity 
was minimal as determined by LDH release. 
 
Knockdown of Sortilin in McA cells using siRNA 
McA cells were transfected using Fugene6 according to manufacturer’s protocol (Promega Corp., 
Madison WI) using three different pGIPZ based vectors expressing shRNAi targeting rat Sort1 
mRNA (V2LMM_58553, V3LMM_450660, V3LMM_450662), and one scrambled, non-
silencing control (GE Healthcare Dharmacon, Lafayette, CO) as previously described 24. 
Puromycin selection was performed on McA cells. Sortilin knockdown (KD) from each cell line 
was examined by immunoblotting. 
 
Immunoblotting 
McA cell lysates were prepared and denatured proteins were separated by SDS-PAGE as described 
previously 43. Membranes were incubated with primary antibodies overnight at 4ºC in blocking 
buffer with antibody binding detected with species specific secondary HRP-linked antibodies and 
developed using Amersham™ Prime reagent (GE Healthcare). Insulin signaling to AKT evaluated 
with Bio-Rad nitrocellulose membranes with phosphospecific (pY, p-AKT(Ser473) and mass 
specific antibodies 28. Chemiluminescence was measured with ChemiDocXRS+ system (Bio-Rad) 
and quantified using Image Lab 3.0.1 software from Bio-Rad (Hercules, CA). Autophagy was 
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measured under three conditions: 1. HPQ (hydroxychloroquine) leads to the accumulation of basal 
LC3-II by blocking fusion between autophagosomes and lysosomes 33,34; 2. E/P (E-64d and 
Pepstatin-A) prevents the fusion of autophagosomes the lysosomes 32; and 3. The control were 
wild type McA. 
 
Immuno-slot blotting 
VLDL and LDL preparations for SPR and MST in Figure 5 were prepared as previously described 
24. Experimental media were adjusted to 1% (v/v) protease inhibitor cocktail I (EMD Millipore) 
and to a salt density of 1.019 g/ml by addition of a solution of NaBr (d = 1.495 g/ml). VLDL was 
isolated by ultracentrifugation in a L-70 Ultracentrifuge (Beckman Coulter, Inc., Fullterton, CA) 
using a 50Ti rotor (200,000 x g, 18 h, 14°C). Following centrifugation, the top 1.5 – 2.0 ml VLDL 
fraction was removed using a syringe and weighed to determine volume. VLDL samples were 
applied in triplicate wells (0.2 to 0.4 ml per well) in a Bio-Dot® SF apparatus (Bio-Rad). Two 
PVDF membranes were used together for blotting: the top was Immobilon-P (IPVH09120 SF) and 
the bottom was Immobilon-PSQ (ISEQ09120 SF); both were obtained from EMD Millipore. 
VLDL-ApoB standards were prepared from rat plasma VLDL and total ApoB (B100 and B48) 
and B100 content were determined on stained gels following SDS-PAGE separation 57. VLDL-
ApoB standards in TBS were slotted in duplicate alongside test samples. After filtration, 0.4 ml of 
TBS was added as a wash. After final filtration, membranes were air dried, rehydrated in methanol 
and incubated in TBS then in blocking buffer at 4ºC overnight. At this stage slot blots were 
evaluated similarly to immunoblotting. After chemiluminescence development and B100 
quantitation, slot blots were stripped by incubation in Restore™ PLUS (ThermoFisher) for 15 min 
at room temperature and were reblocked overnight at 4C. Total ApoB (B100 and B48) present in 
VLDL was then evaluated following incubation with rabbit polyclonal anti-rat ApoB. The bottom 
PVDF membrane was carried through the entire procedure to assure there was no “bleed through” 
of test samples. VLDL-ApoB and VLDL-B100 content were calculated from standard curves 
generated by VLDL-ApoB standards. Recovery of rat VLDL added to unspent media averaged 
94% ± 4.9% with a CV of 5.2% (n = 6 replicates). 
 
Computational modeling and compound screening 
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Schrödinger’s Maestro program (version 9.3.5) was used as the primary graphical user interface 
and Maestro version 10.2 (Schrödinger, LLC, New York, NY) was used for ligand interaction 
diagramming. Virtual screening was performed on compounds contained in ChemBridge libraries 
(www.chembridge.com) that were prepared with Schrödinger’s LigPrep program (Schrödinger, 
LLC, New York, NY). The virtual screening method was performed using Schrödinger’s GLIDE 
software 58 on the Sortilin crystal structure PDB ID: 4PO7 27. Compounds were docked on grids 
generated with Glide with cpd541 docked at a box determined by C-terminal NT and cpd984 
docked at a box determined by the N-terminal fragment of NT. Grids were then adapted from 
alignment of PDB ID:6EHO to PDB ID: 4PO7 and docking performed for all grids using Glide 
XP setting with results exported into Graphpad Prism. 
 
MD Simulations of apo and holo Sortilin  
Using the aforementioned crystal structure of Sortilin (PDB ID:4PO7) molecular dynamics 
simulations were done using NAMD 2.12 59 using the CHARMM36m force field 60. Prior 
simulating, the system was prepared using the CHARMM-GUI solution builder, with a salt 
concentration of 150 mM NaCl. Simulation parameters included constant pressure of 1 atm via 
Langevin dynamics, as well as a constant temperature of 310 K using Langevin piston 
Nosé−Hoover methods 61,62. Long-range electrostatic forces were evaluated using the particle 
mesh Ewald (PME) with a 1 Å grid spacing 63,64. Van der Waals interactions were calculated using 
a 12 Å cutoff with a force-based switching scheme after 10 Å, as well as a 2 fs time step integration 
via the SETTLE algorithm 65.  Visualization and analysis was done using VMD 1.9.3 66. The 
system was equilibrated for 20 ns restraining the Cα atoms of the protein (1.0 kcal/mol/Å2) to 
allow for solvation. This was followed by a production run of 50 ns without restraints for 4 poses 
taken from ensemble docking, 3 poses with the highest affinity pose for Site-1 of Sortilin run in 
duplicate for each, and the pose for Site-2 that represented the predicted pose as shown previously 
17. 
  
Ensemble Molecular Docking of cpd541 and cpd984 
To probe cpd541 and cpd984 interactions with Sortilin, ensemble molecular docking was 
employed as described 67. Using snapshots from the 50 ns production simulation to sample protein 
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dynamics, snapshots were taken every 200 ps. Each of the resultant 250 snapshots were used to 
dock cpd541 and cpd984 using a 100Å by 90Å by 70Å grid box. Docking was done with an 
exhaustiveness of 10, yielding a total of 2500 docked poses. Resultant poses were clustered using 
a hybrid K-centers/K-medoids algorithm, utilizing an RMSD method 68,69. Representative poses 
with highest scoring affinities in clusters closest to Site-1 and Site-2 were selected for further 50 
ns simulations. The resultant drug bound simulations were analyzed with VMD as well as 
MDAnalysis 70,71. 
   
Protein-Protein Docking and Simulations 
Characterization of protein-protein interactions between Sortilin (PDB:4PO7) and PCSK9 
(PDB:2P4E) was done using the default settings of webserver ClusPro 71-73. The top three output 
poses where simulated for a production run of 10 ns using MD protocols as for Apo and Holo 
Sortilin. Interacting residue analysis was done using VMD with a 3.5 Å cutoff, over each of the 10 
ns trajectories and exported into GraphPad Prism for analysis. Root mean squared fluctuations 
(RMSF) of Cα atoms of the proteins Sortilin and PCSK9 were analyzed and exported from VMD 
and plotted using GraphPad Prism. 
 
Microscale Thermophoresis 
Thermophoresis measurements were performed using a Monolith NT.115 labeled thermophoresis 
instrument 72,73. Sortilin-His6 was labeled with Ni-NTA Atto-488 according to the manufacturer’s 
protocol as previously described 73,74. M.O. Control software was used for operation of MST. 
Target protein concentrations were 50 nM for Sortilin labeled protein. LED excitation power was 
set to 90% and MST set to high allowing 3 sec prior to MST on to check for initial fluorescence 
differences, 25 sec for thermophoresis, and 3 sec for regeneration after MST off. Analysis was 
performed using M.O. Affinity Analysis Software as the difference between initial fluorescence 
measure in the first 5 sec as compared with thermophoresis at 15 sec. All measurements were 
performed in PBS buffer (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4, pH 
7.4) without Tween and binding affinity was generated using Graphpad Sigmoidal 4PL fit from 
points exported from M.O. Affinity Analysis software using KD Model with target concentration 




Surface Plasmon Resonance 
Surface plasmon resonance measurements were performed on a Biacore T200 instrument equipped 
with CM5 sensor chips with ~2000 response units (RU) of Sortilin covalently immobilized to the 
surface for VLDL and LDL binding, ~3500 RU crosslinked Sortilin for small molecule binding, 
and a CM5 with ~6500 RU crosslinked Sortilin for both NT and nanodisc binding. Lipid 
composition of nanodiscs consisted of 3.023 µmol dipalmitoyl phosphatidylcholine (PC), 0.098 
µmol diC16-PIP3, and 0.78 µmol 1-palmitoyl, 2-oleoyl phosphatidylethanolamine (PE), which 
were prepared as previously described 17. HBS-DMSO running buffer (10 mM HEPES pH 7.4, 
150 mM NaCl, 1% DMSO) was used at a flow rate of 30 μl/min and injections performed with 
times for association of 90 sec, and dissociation of 300 sec, followed by injection of buffer to 
regenerate the Sortilin surface. Regeneration for Ni-NTA non-covalently linked nanodisc 
experiments utilized EDTA 24.  Regeneration for CM5 NHS/EDC crosslinked Sortilin required a 
30 sec injection of 10 mM NaOH as previously described 17. Binding was expressed in relative 
RU; the difference in response between the immobilized protein flow cell and the corresponding 
control flow cell. NT, cpd984, 5% PI(3,4,5)P3 containing nanodiscs and VLDL/LDL were 
administered to chips containing Sortilin with 1:1 titrations and results exported from BiaEvaluate 
software into GraphPad prism (GraphPad Software). Cpd984, cpd541 and PI(3,4,5)P3 saturation 
curves were fit using a specific binding equation with hill slope, whereas all other SPR saturation 
curves were fit using a 1:1 specific binding model. 
 
Vacuole Isolation and in vitro vacuole fusion assay 
Vacuoles were isolated from BJ3505 75 and DKY6281 76 , which were used for fusion assays by 
density gradient floatation as previously described 72. Fusion reactions (30 µL) contained 3 µg 
each of vacuoles from BJ3505 (pep4∆ PHO8) and DK6281 (PEP4 pho8∆), fusion assay buffer 
(125 mM KCl, 5 mM MgCl2, 20 mM PIPES-KOH pH 6.8, 200 mM sorbitol), ATP regenerating 
system (1 mM ATP, 29 mM creatine phosphate, 0.1 mg/ml creatine kinase), 10 µM CoA, and 283 
nM Pbi2p and buffer or cpd984. Reactions with or without cpd984 were incubated at 27C for 90 
min and the Pho8 activity was measured in 250 mM Tris-Cl PH 8.5, 0.4% Triton X-100, 10 mM 
MgCl2, 1 mM p-nitrophenyl phosphate. Fusion-dependent alkaline phosphatase maturation was 
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measured by the amount of p-nitrophenylate produced. p-Nitrophenylate absorbance was 
measured at 400 nm.   
Yeast Western Analysis and CPY Secretion 
Vacuoles of BJ3505, DK6281, and their vps10 derivatives were isolated and vacuoles were 
removed by centrifugation (16,000 x g, 5 min, 4C) and SDS sample buffer was added to the 
supernatants. Samples were heated at 95C for 5 min, resolved by SDS-PAGE, transferred to 
nitrocellulose, and probed by Western blot in. CPY secretion was measured with vacuoles from 
BJ3505 and SEY6210 yeast strains incubated with cpd984 were grown at a volume of 1L overnight 
as done for yeast fusion. A 10 mL sample of YPD media was taken before harvest and spun down 
to remove cell lysate. TCA precipitation was performed resuspending pellet in approximately 100 
µL SDS sample buffer, run on SDS-PAGE and blotted for CPY 77. The remaining 990 mL of YPD 
was used for harvesting vacuoles. Vacuoles were measured using Bradford reagent and normalized 
prior to running SDS-PAGE along with a loading control.  
Statistics 
Unless noted, results are expressed as the mean ± S.E.M., where n equals the number of 
independent experiments in which replicate analyses were performed in each experiment. 
Significant differences were assessed using Student’s t-test with p-values ≤ 0.05 being considered 
significant. 
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Figure 4.1. Experimental and Computational Characterization of cpd541 and cpd984. a, SPR 
determined binding affinity of cpd984 to on CM5 chip loaded with ~3000 RU of human Sortilin 
with saturation curve (blue) indicating KD 118 ± 38 nM. b, SPR as in 1a, of cpd541 to Sortilin with 
saturation curve (red) KD 6.9 ± 1.1 µM. c, SPR as in 1a and 1b with cpd984 titration in the presence 
(green) and absence (blue) of 10 µM cpd541 with saturation curves. d, Resultant poses from 
ensemble docking for cpd984 (purple) and cpd541 (cyan) at Site-2 of Sortilin alone and 
superimposed. e, Percent of overall poses from ensemble docking versus relative docking score 
for cpd984 (red) and cpd541 (blue) where the Y axis is the percent of all poses for ensemble 
docking that bind site 2 of Sortilin, with cpd984 having about 9 % percent of all poses in site 2 and 
cpd541 having about 3 percent of all poses.  f, Schrodinger Glide Xp scores of cpd541 and cpd984 
docked in site 1 and site 2 of ~pH7 PDB ID: 4PO7 and ~pH5.5 PDB ID: 6EHO. 

















118 ± 38 nM
h = 2 ± 1.2












6.9 ± 1.1 mM












984 + 10 mM 541
Figure 1
cpd541 & cpd 984
 at Site-2
cpd541 at Site-2cpd984 at Site-2







































Sort pH 7 4PO7 Site 1
Sort pH 7 4PO7 Site 2
Sort pH 5 6EHO Site 1







Figure 4.2. Computational Characterization of cpd984 to Sortilin Site-1 and Site-2. a, 
Simulations of bound cpd984 poses taken from ensemble docking as in Figure 1d, 1e with Site-2 
pose taken from closest ensemble docking pose to pose (n=6) and the three highest scoring poses 
for cpd984 to Site-1 (n=2 each) based on ensemble docking. Center of mass difference over time 
(50 ns) between cpd984 and representative residue of Site-1 R292 for the three duplicate 
simulations of cpd984 to Site-1 are shown in red, whereas center of mass differences between 
cpd984 and representative residue of Site-2 Leu539 for the six duplicate simulations of cpd984 to 
Site-2 are shown in blue. b, Ligand interaction diagram taken from a representative simulation 
from Figure 2a of cpd984 to Site-2 of Sortilin at the end of the 50 ns MD simulation. c, Center of 
mass difference over time as in Figure 2a between cpd984 and a representative residue of the 
hydrophobic ligand binding pocket of Sortilin adjacent to Site-2 Phe555 of six simulations of Site-
2 bound ligands). d, Simulations of bound cpd541 as in Fig. 2a, with center of mass taken from 
Arg202 and Leu539 as in Fig. 2a, from top 3 cpd541 ensemble docking poses in site 2 (n=2) and 
cpd541 poses from site 1 with a salt bridge between cpd541 and Arg292. e, Residue analysis for 
all 24 50 ns simulations of cpd984 and cpd541 in site 1 and site 2 of Sortilin with fraction time 
bound calculated by determining number of frames (5000) where a residue of Sortilin was within 
3.5 Å of either cpd984 or cpd541. C-term and N-term NT used as a legend at 100% over the one 
frame taken from PDB coordinates of PDB ID: 4PO7. f, Ligand interaction diagram taken from a 
representative simulation from Figure 2d of cpd541 to Site-1 of Sortilin at the end of the 50 ns MD 
simulation. 
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Figure 4.3. Cpd984/cpd541 Differential Effects on NT Binding and ApoB Secretion ion McA 
Cells. a, SPR analysis following administration of 100 nM NT alone and in the presence of either 
cpd984 or cpd541 at concentrations of 10 and 100 μM. RU subtractions of cpd984 and cpd541 
alone were performed for injections at the corresponding concentrations in the presence of 
neurotensin in order to depict the effect of these compounds on the binding of neurotensin to 
Sortilin. b, McA knockdowns with varying levels of Sortilin were measured for secretion of 
VLDL-B100 into media and assessed by immuno-slot blot. The effect of Sortilin KD on VLDL-
B100 secretion and VLDL-ApoB secretion by insulin sensitive McA cells (1% BSA/DMEM). 
Results are the average of triplicate plates for each condition ± S.D. * p<0.05. c, Insulin sensitive 
McA were incubated with increasing concentrations of cpd541 or cpd984 and secretion of VLDL-
































































Figure 4.4. PIK-III Increases Secretion of Both ApoB and PCSK9. a, Measurement of 
autophagic protein expression in the presence and absence of wortmannin and PIK-III Cellular 
proteins were analyzed by IB for LC3-I, LC3-II, p62, and GAPDH using HRP-linked secondary 
antibody and ECL detection. Loading controls included GAPDH (cb1001mAb (6C5)). McA cells 
were incubated in 1% BSA/DMEM with DMSO, wortmannin or PIK-III for 18 h. Band intensities 
were measured using ChemiDocXRS+ system and evaluated using ImageLab 5.1 software. b, 
Measurement of AKT pathway as in Figure 4a with (5, 10, and 20) and without insulin (0) in the 
presence and absence of PIK-III and wortmannin blotting for both AKT and pAKT with ratios 
depicted on the bottom. c, Measurement of total ApoB as in Figure 4a in both the media and 
infranatant in the presence and absence of PIK-III and wortmannin. d, Measurement of cellular 
Sortilin, LDLR (LS-C146979, 1:2000), PCSK9 (Ab125251, 1:2000) and GAPDH as in Figure 4a, 
in the presence and absence of PIKIII and wortmannin. e, Quantification of LDLR, Sortilin, and 











--- E/P HCQ E/P HCQ E/P HCQ kDa
 
+++-
  0  5   10  20
+++-
  0  5   10  20
+++-
  0  5   10  20
Control PIK-III













































































































































































Figure 4.5. Effects of Cpd541 and Cpd984 on PCSK9/LDLR Expression and Potential Role 
of PI(3,4,5)P3 in Sortilin Binding to ApoB-Lp. a, McA cells were incubated in 1% BSA/DMEM 
with DMSO, cpd541 (10 μM) or cpd984 (10 μM) for 18 h. Cellular proteins were extracted and 
analyzed by IB for LDLR (LS-C146979, 1:2000) or PCSK9 (Ab125251, 1:2000) using HRP-
linked secondary antibody and ECL detection. Loading controls included – -Actin (Rockland 
ph600-401-886) and GAPDH (cb1001mAb (6C5)). Band intensities were measured using 
ChemiDocXRS+ system and evaluated using ImageLab 5.1 software. b, Results from ClusPro 
protein-protein docking simulation of Sortilin PDB ID: 4PO7 to PCSK9 PDB ID: 2P4E with 
Sortilin in blue, PCSK9 in grey, blade 1 of Sortilin in red. c, Residue analysis as in Figure 2e 
corresponding to three 10 ns simulations of PCSK9 to Sortilin using PDB files in Figure 5b with 
mean fraction bound as in Figure 2e for PCSK9 to Sortilin with 984 results from Figure 2e plotted 
in green, PCSK9 residue.  d, RMSF analysis of Sortilin residues from ClusPro simulation of 
Sortilin PDB ID: 4PO7 to PCSK9 PDB ID: 2P4E e, RMSF Analysis of PCSK9 residues from 
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Figure 4.6. Cpd984 modulates binding to PI(3,4,5)P3. a, SPR as in Figure 1a of diC8-PI(3,4,5)P3 
binding measurements in the presence and absence (red) of 10 µM cpd984 (blue) and cpd541 
(green) with KD. b, SPR using a CM5 chip crosslinked with Sortilin. c, Labeled microscale 
thermophoresis (MST) using Atta-647 Ni-NTA labeled Sortilin measured in the red channel with 
a constant concentration of Sortilin of 12.5 nM and 32 different concentrations of VLDL and LDL 
run in triplicate and analyzed using Nanotemper M.O. Affinity Analysis software with KD for 
VLDL of ~4 nM and for LDL of ~74 nM. d, SPR performed using a CM5 chip containing ~2000 
RU of Sortilin with KD for VLDL of ~5 nM and for LDL of ~54 nM.   
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Figure 4.7. cpd984 affects CPY sorting in Yeast. a, Immunoblots of wild type and vps10 cell 
lysates with antibody against the late endosomal/lysosomal Rab Ypt7, the yeast Sortilin ortholog 
Vps10, the luminal protease CPY, and actin as a loading control. b, Relative concentrations of 
intracellular CPY in untreated WT cells vs cells treated with cpd984. c, Immunoblot of secreted 
CPY in cells treated with cpd984. d, In vitro homotypic vacuole fusion assays with wild type and 
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Chapter 5: General Discussion 
 
Sorting and fusion pathways are intertwined, as most sorting pathways are dependent on specific 
SNARE components to each organelle in order to regulate trafficking generally 1.  Measuring 
fusion at a particular organelle such as the yeast vacuole can be utilized as a marker for protein 
sorting given the hypothesis that the particular pathway of interest represents a significant amount 
of traffic to a given organelle 2.  There are many different assays of fusion to measure definable 
stages of fusion such according to four stages: 1. Priming, 2. Docking, 3. Tethering, and 4. Fusion 
2.  Assays measuring levels of vacuole fusion for a given stage of fusion, allow the ability for a 
researcher to further define activity of a given fusion regulator on fusion components operating at 
a given stage of fusion, such as priming 3.  As shown in Chapters 2-4, these techniques can serve 
as a platform to discover probes for fusion machinery or for sorting pathways targeted to the 
vacuole.  
 
Defining Lipid-Protein Interactions 
Various computational approaches can be utilized to identify protein-lipid binding interactions 
surfaces 4.  Multiple approaches were utilized to determine potential interaction regions for Sec18 
binding to PA as well as sortilin to PIP3.  Among the approaches utilized were a binding site 
determining software approach based on the potential for a given protein to serve as a small 
molecule binding site 5.  This approach can serve to both to identify estimated binding affinities of 
short chain lipids to regions of a protein of interest as well as give potential poses that can be 
utilized for further simulations.  In order to generate additional potential poses and to discriminate 
regions of affinity of a protein for a given lipid, ensemble docking was used in Chapter 2 to identify 
Di-C8 PA binding regions of Sec18.  This technique was capable of utilizing MD to further allow 
probing of Sec18 D1-D2 domain molecular movement effect on DiC8 PA binding.  Similarly, in 
Chapter 2 molecular flooding was utilized to confirm regions of Sec18 with affinity to Di-C8 PA.  
 
Once a researcher has selected regions of a protein-lipid interaction of highest interest, further 
characterization of the protein-lipid binding event can be achieved using MD approaches.  In 
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Chapter 2, MD simulations were performed of the highest affinity poses of Di-C8 PA from 
ensemble docking to Sec18.  These simulations directly corresponded to SPR and MST binding 
affinity experiments performed using His7-Sec18 allowing comparison between dry and wet lab 
results.  Additionally, HMMM simulations were performed to determine the interaction of Sec18 
to PA containing membrane bilayers.  This simulation directly corresponded to SPR and MST 
binding affinity experiments performed on purified His7-Sec18 and GST-Sec18 to PA liposomes 
and PA nanodiscs.  Furthermore, HMMM simulations more closely approximates the biologically 
relevant binding mechanism of Sec18 to PA containing cellular organelles.   
 
The MD simulations in Chapter 2 provided valuable information about both the regions of Sec 18 
that are important for PA binding as well as the mechanism by which Sec18 binds to PA.  For this 
interaction, conformational change was determined to be a major factor as to how Sec18 binds PA.  
Furthermore, this conformational change of Sec18 was shown to be necessary for PA binding as 
shown in Chapter 3.  As shown in Chapter 3, the information gathered about Sec18 binding to PA 
was utilized to discover a small molecule probe to the Sec18 binding interface for PA.   The ability 
to interpret conformational changes with computational approaches continues to be refined, but 
herein lies an example of how this information can be both utilized and built upon for studying 
lipid protein binding interactions.   
 
Discovering Probes to Affect Lipid-Protein Binding Interactions 
Small molecule probes were discovered for both Sec18 binding to PA (Chapter 3) and Sortilin 
binding to PIP3 (Chapter 4).  In  both instances, the binding regions for virtual target screening 
(https://www.ncbi.nlm.nih.gov/pubmed/17034125) was identified using Schrodinger SiteMap 6 to 
first identify potential binding to a non-biological short chain lipid of either PA for Sec18 or PIP3 
for sortilin.  This allowed for the identification of a novel site 2 of sortilin for cpd984 7, the 
hypothesis that PIP3 bound to site 1 of sortilin predominantly 8, and the discovery that IPA 





Virtual target screening generally is more accurate with better structural resolution 9, however, 
Sec18 does not have a fully resolved crystal structure 10.  NSF was resolved using phasing from 
crystal structures of the D2 11 and N domain 12 coupled with high resolution Cryo-EM 13 to achieve 
full resolution atomistic characterization of the AAA ATPase mammalian NSF at 7.6 and 4.2 
angstroms respectively for ADP and ATP bound hexameric NSF.  This structural information is 
misleading however, as portions of NSF used for this structure have higher resolution.  In Chapter 
2, structural information from these structures was used to identify PA binding regions of the Sec18 
yeast homologue of NSF Sec18.  The binding site information from Chapter 2 was utilized in 
Chapter 3 to identify IPA using the Chembridge Microformat library.  Hits from this screen were 
tested for fusion and more specifically priming inhibition before characterizing their biological 
effect in yeast.  This approach was sufficient for discovering the first specific small molecule 
inhibitor of priming IPA, however, without MD approaches, mechanistic explanations for IPA 
effect would not have been elucidated.  The ability to characterize conformational responses of 
Sec18 to IPA binding indicated a more complex mode of action for IPA in priming regulation of 
Sec18 involving conformational stabilization with administration of IPA.   
 
This same Chembridge library was used for virtual screening small molecules to the sorting protein 
Vps10 (yeast) or sortilin (mammalian).  Previous research groups have identified small molecules 
to the canonical NT binding cavity of sortilin using virtual screening 14, and similar screening was 
performed for the identification of site 1 compound cpd541.  However, short chain PIP3 docking 
of sortilin facilitated by Schrodinger SiteMap indicated two potential high affinity binding sites of 
sortilin.  Screening the non-canonical site of sortilin allowed for identification of site 2 compound 
cpd984 7.  MD was utilized to further characterize the interaction of these molecules with sortilin 
in Chapter 4.  Ensemble docking indicated greater enrichment of cpd984 at site 2 of sortilin.  This 
was further corroborated by MD studies indicating that cpd984 stayed bound to site 2 over 50 ns, 
whereas it came out of site 1 within 50 ns on average.  This process was repeated for cpd541 
indicating that it stayed bound to site 1 over 50 ns, whereas it came out of site 2 within 50 ns on 
average.  This technique was provided computational context and support for the hypothesis that 
site specificity of sortilin allows differential sorting regulation.  




Diverse computational techniques were utilized to discover protein binding regions to lipids along 
with companion protein-lipid probes.  The corroboration of discoveries made computationally with 
well established wet lab techniques allowed for further characterization of these interactions.  
Though computational techniques such as molecular dynamics are gaining increased utilization in 
the scientific community, it is still advantageous to corroborate these insights with wet lab 
verification.  Molecular dynamics approaches to drug discovery were not utilized in the drug 
discovery process outlined in Chapter 3 and 4, however, these approaches will be utilized for the 
next generation of virtual screening for these projects.  Taking slices of protein trajectories  
solvated in buffer with and without membranes allows for sampling of different protein 
conformations in the drug discovery process.   This plethora of structural information should allow 
enrichment of virtual screening docking results in the future giving optimism towards a structure-
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